



	1115
1	IN THE UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS
2	EASTERN DIVISION
3 4	WENDY B. DOLIN Individually and as Independent Executor of the Estate of STEWART DOLIN, deceased,
5	Plaintiff,
6	vs.) Chicago, Illinois
7	SMITHKLINE BEECHAM CORPORATION D/B/A GLAXOSMITHKLINE, a Pennsylvania
8	Corporation, March 22, 2017
9	Defendant.) 9:20 o'clock a.m.
10	VOLUME 6 A
11	TRANSCRIPT OF PROCEEDINGS BEFORE THE HONORABLE WILLIAM T. HART
12	
13	For the Plaintiff:
14	BAUM, HEDLUND, ARISTEI & GOLDMAN, P.C. BY: R. Brent Wisner
15	Michael L. Baum 12100 Wilshire Boulevard
16	Suite 950 Los Angeles, California 90025
17	(310) 207-3233
18	RAPOPORT LAW OFFICES, P.C.
19	BY: David E. Rapoport Matthew S. Sims
20	20 North Clark Street Suite 3500 Chicago Illingia 60602
21	Chicago, Illinois 60602 (312) 327-9880
22	Court reporter:
23	Blanca I. Lara, CP, CSR, RPR
24	219 South Dearborn Street Room 2504
25	Chicago, Illinois 60604 (312) 435-5895


1	Appearances (continued:)
2	
3	For Defendant GlaxoSmithKline:
4	KING & SPALDING
5	BY: Todd P. Davis
6	Andrew T Bayman Heather Howard 1180 Peachtree St Ne
7	Atlanta, Georgia 30309 (404) 572-4600
8	KING & SPALDING LLP
9	BY: Ursula M. Henninger Suite 3900
10	100 N Tryon Street Charlotte, NC 28202 (704) 503-2631
11	(704) 503-2631
12	SNR DENTON US. LLP
13	SNR DENTON US, LLP BY: Alan Scott Gilbert 233 South Wacker Drive
14	Suite 7800 Chicago, Illinois 60606
15	(312) 876-8000
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	














		Ross - direct by Wisner 1123
	1	Q. Doctor, we were looking at Plaintiff's Exhibit 9. What
	2	document is this?
	3	A. So this is a 2006 letter from GlaxoSmithKline to the FDA,
	4	specifically to the division director of psychiatry products at
09:38:17	5	CDER division that regulates Paxil. And I believe this is the
00.0011/	6	results of GSK's analysis of suicidal behavior and other events
	7	occurring in Paxil.
	8	Q. Okay. We were discussing this document yesterday, do you
	9	recall?
09:38:47	10	A. Yes.
	11	Q. Okay. And in this letter there is a paragraph that we were
	12	talking about. And I'll pop it up right here. It says:
	13	" in adults with MDD all ages, there was a
	14	statistically significant increase in the
09:39:03	15	frequency of suicidal behavior in patients
	16	treated with Paroxetine compared with placebo.
	17	However, the majority of these attempts for
	18	Paroxetine, 8 of 11, were in younger adults
	19	age 18 through 30 years. These MDD data suggest
09:39:21	20	that the higher frequency observed in the
	21	younger adult population across psychiatric
	22	disorders may extend beyond the age of 24."
	23	Now, Doctor, is that discussion of the majority of
	24	the suicide attempts occurring in younger adults age 18
09:39:40	25	through 30 an accurate statement?

		Ross - direct by Wisner 1124
	1	A. No.
	2	Q. How so?
	3	A. The words if you could just highlight these for me?
	4	Q. Sure.
09:39:49	5	A. Or highlight not for me but for the Court.
	6	(Short interruption by the court reporter.
	7	BY THE WITNESS:
	8	A. If you could highlight the words, and this is on the third
	9	line, "the majority of these attempts for Paroxetine."
09:40:21	10	Q. Okay. What's wrong with that, Doctor?
	11	A. Well, it's, at best, misleading, and at worse, false. You
	12	could say that 8 of 11 were younger adults age 18 to 30 and
	13	that will be a correct statement; however, you could also say,
	14	as I pointed out yesterday, that 8 of the 11 were in adults
09:40:46	15	aged 25 and up, and that would also be correct.
	16	Q. Well, then, Doctor, if this paragraph or something similar
	17	to it with that the majority-of-attempts language were to be
	18	put into the Paxil label, would that make the Paxil label
	19	adequate or no longer misleading?
09:41:11	20	A. So just so I'm clear, this statement what you are saying
	21	is the statement saying the majority of these attempts for
	22	Paroxetine?
	23	Q. Correct. If they put something like that in the label,
	24	would that have made the label no longer misleading?
09:41:26	25	A. No.

		Ross - direct by Wisner 1125
	1	Q. So
	2	A. It would've been more misleading, actually.
	3	Q. In fact, did GSK put this language in the label in 2006?
	4	A. It did.
09:41:37	5	Q. And did it do so without prior approval from the FDA?
	6	A. That is correct.
	7	Q. How can a drug manufacturer just put something in the label
	8	without getting approval from the FDA first?
	9	A. So the regulations allow a manufacturer to add or
09:41:56	10	strengthen a warning on its own with the proviso that the FDA
	11	can review it, and based on the review, ask it to change the
	12	language.
	13	And, in fact, if any recall correctly, there was quite
	14	a period of time between GlaxoSmithKline adding this language
09:42:18	15	and the FDA completing its review. It's not like at the FDA
	16	I conducted and supervised, I would say, hundreds of these
	17	reviews. These are called Changes Being Affected where the
	18	manufacturer tells the FDA, hey, we think there's information
	19	that is important here for a warning, we want to get it out
09:42:45	20	there as soon as possible, we're letting you know because we
	21	know you're eventually going to have to approve it, but we want
	22	to get it out there.
	23	And so they basically give them 30 days notice and
	24	then they can start printing it up and sending it out, and they
09:43:03	25	do. And in my experience, it's extremely unusual for changes

	1	being affected supplement to get reviewed by the FDA in less
	2	than 30 days. If the FDA comes back and says, no, we think you
	3	need to change this, it's not like the manufacturer suddenly
	4	has to immediately pull back what it's done, it works with the
09:43:25	5	FDA to come up with new language and then it prints new
	6	labeling. But the idea is that to add or strengthen a warning
	7	the sponsor can when I say "sponsor," I'm sorry, more jargon
	8	there, but the manufacturer can do that on its own. Has to let
	9	the FDA know, but it can do it on its own.
09:43:44	10	Q. So GSK specifically uses this regulation to add this
	11	regulation to the label in 2006?
	12	A. That is correct.
	13	Q. Do you believe that by adding this language it made the
	14	label sufficient?
09:43:56	15	A. I think it made the label worse.
	16	Q. All right. Now, I want to get closer in time to the
	17	present. In 2007 what happened with the labeling for Paxil?
	18	A. So on the basis of analyses that pharmaceutical companies,
	19	manufacturers of SSRIs had done and that the FDA had done, the
09:44:26	20	FDA requested manufactures of SSRIs to add what I talked
	21	yesterday, class labeling, labeling that applies to a
	22	particular class of drugs, and in this case it was SSRIs. And
	23	that involved the potential for suicidal behavior to emerge in
	24	connection with people getting started on those drugs.
09:44:54	25	Q. Was it limited to a certain age group?

		Ross - direct by Wisner 1127
	1	A. It was.
	2	Q. What was that age group limitation for the class labeling?
	3	A. For just looking at the class of all antidepressants and
	4	all SSRIs, it was that class labeling across all drugs was 18
09:45:20	5	to 24.
	6	Q. Did that class labeling warn that Paxil could induce
	7	suicidal behavior in adults over 24?
	8	A. No, it did not.
	9	Q. Do you believe that GSK had an obligation to put that in
09:45:38	10	the label after the class labeling?
	11	A. Yes.
	12	Q. All right. I want to talk about the label that existed in
	13	2010 for Paxil when Stewart Dolin passed away.
	14	Have you reviewed that label, Doctor?
09:45:59	15	A. I have.
	16	Q. And have you gone through it in detail and figured out what
	17	was the problem or what needed to be added to it?
	18	A. I did exactly the same thing I did when I was a medical
	19	reviewer and a medical team leader at FDA in terms of analyzing
09:46:17	20	the label and saying, we're going into labeling negotiations
	21	with the manufacturer, what do we think should be put in and
	22	where.
	23	Q. And did you did you mark up the label, different color
	24	pens and everything?
09:46:35	25	A. I did.

1 Q. 0kay. I'm going to go through that label with you in just 2 one second, but before I do that let me just ask you a simple 3 What is wrong with the 2010 Paxil label as it question: 4 relates to adult suicidal behavior over the age of 24? 5 A. So it does not say anything about Paxil in particular. It just talks about all antidepressants, all SSRIs. It doesn't 6 7 mention anywhere in there that the data that we discussed 8 yesterday show that the risk of inducing suicidal behavior in 9 patients getting Paxil is not just for people under 24, 24 and 10 under, it extends to older ages.

11 So basically by being silent on that, it leads people, 12 prescribers specifically, to think what applies to those 13 antidepressants--that is, risk is restricted to people 24 and 14 under--must be true for Paxil, even though that is really not 15 true. It is silent on that. And so it's almost like Paxil is 16 getting a free ride on the other antidepressants.

17 Q. Have you seen any analysis done by the FDA that shows that18 Paxil is, in fact, worse than the other SSRIs?

19 A. Yes.

09:48:16

09:46:54

09:47:29

09:47:55

20 Q. And what analysis is that, Doctor?

A. So two reviewers at FDA analyzed the data that all these
pharmaceutical manufactures had brought in in 2006. And the
names of these reviewers were Dr. Stone and Dr. Jones, and so
I'll refer to that as the Stone/Jones report.

09:48:39

25

MR. WISNER: Your Honor, permission to publish Joint

1128

		Ross - direct by Wisner 1129
	1	Exhibit 13. It's in evidence.
	2	THE COURT: You may proceed.
	3	(Exhibit published to the jury.)
	4	BY MR. WISNER:
09:48:46	5	Q. Doctor, I'm putting it up on the screen. Is that the
	6	Stone/Jones report?
	7	A. Yes.
	8	Q. All right. And in this report did the authors from the FDA
	9	break down the drugs for all ages, all SSRIs for all ages in
09:49:03	10	the risk of suicidal behavior?
	11	A. Yes, they did.
	12	Q. I'm going to get to it right now.
	13	I'm looking at table 16, Doctor. Is this the table
	14	you're referring to?
09:49:20	15	A. Yes.
	16	Q. It says "all drugs" and it has an odds ratio of 1.1, do you
	17	see that?
	18	A. Yes.
	19	Q. And that's referring to not just SSRIs but every other
09:49:31	20	conceivably antidepressant?
	21	A. All the antidepressants that were analyzed in this report,
	22	yes.
	23	Q. Thank you. I guess you can see this.
	24	A. Yes.
09:49:38	25	Q. All right. Then we have the SSRIs, risk ratio for all

		Ross - direct by Wisner 1130
	1	SSRIs, and what is that, Doctor?
	2	A. So this is basically the ratio of the relative it's
	3	not the relative risk, but it's how manyfold what's the
	4	increase in the chances that a patient is going to show
09:50:03	5	suicidal behavior on this particular drug that's listed here,
	6	the 6 drugs, compared to patients who just get placebo.
	7	Q. And it has 1.23. Does that mean the best estimate of this
	8	analysis is that SSRIs increase suicidal behavior by
	9	approximately 23 percent?
09:50:23	10	A. That is correct.
	11	Q. Okay. Now, the list of SSRIs here, do you see the one
	12	related to Paxil?
	13	A. I do.
	14	Q. And what is the point estimate for that one?
09:50:34	15	A. So it's 2.76. In other words, the risk is increased
	16	over the placebo if you had the placebo listed here, that
	17	would be 1.0.
	18	Q. Now, if you look over on the right there's a confidence
	19	interval, do you see that?
09:50:52	20	A. Yes.
	21	Q. And you also see the P value, do you see that?
	22	A. Yes.
	23	Q. All right. What which drugs have a confidence interval
	24	that actually is above 1?
09:51:04	25	A. So what if I can take a second and say, and

	1	Dr. Healy may have covered this yesterday, but the confidence
	2	interval is where we think this 2.76 is just an estimate.
	3	You say, well, is that really what the value is? The true
	4	value, if you were to do this an infinite number of times would
09:51:29	5	likely fall between in the confidence interval.
	6	So if the confidence interval does not include
	7	1remember, 1 is where a placebo is then that is makes it
	8	very likely that this is not just some chance finding, but, in
	9	fact, is very real.
09:51:52	10	Q. Is there any significance to the fact that among all the
	11	SSRIs for which there was that class-wide label, only Paxil has
	12	a confidence interval of above 1?
	13	A. From a regulatory standpoint, and I would also say from a
	14	clinical standpoint, I would draw the conclusion from this that
09:52:17	15	Paxil has a higher risk we're sure it has a higher risk,
	16	perhaps I should put it that way, compared to the other SSRIs
	17	of inducing suicidal behavior.
	18	Q. Doctor, to clear it up, I want to make sure the record is
	19	clear, because we're concerned about the transcript. So if the
09:52:46	20	confidence interval is above 1
	21	A. Yes.
	22	Q is that what shows that you have a particularly bad
	23	problem?
	24	MR. BAYMAN: Objection, Your Honor.
09:52:56	25	THE COURT: Overruled.

		Ross - direct by Wisner 1132
	1	BY THE WITNESS:
	2	A. Yes, you're you're much more certain that you have a bad
	3	problem.
	4	BY MR. WISNER:
09:53:04	5	Q. Now, if the confidence interval falls below 1, does that
	6	mean you don't have a problem?
	7	A. No; it may just mean that you haven't looked at enough
	8	patients. If it doesn't cross 1, you can be very sure.
	9	Q. And if the confidence interval, let's say, goes below 1,
09:53:20	10	could it also be that the studies that you're using the data
	11	from weren't designed to pick up the risk?
	12	A. That's exactly right. And I'm sorry. Please go ahead.
	13	Q. Okay. If you want to complete your answer, you're welcomed
	14	to. Did you want to say something else?
09:53:37	15	A. Yeah. These studies were all designed to show that the
	16	drug or test that the drug works. If you want to set out to
	17	see what the risk is for a drug, you need to study enough
	18	patients to do so.
	19	There's a rule of thumb that says if you have a side
09:53:57	20	effect that occurs 1 percent of the time, that is 1 out of 100,
	21	in order to detect it reliably you need to study 3 times as
	22	much patients, in other words, 300 patients.
	23	So if I have a very unusual eventlike fortunately
	24	suicide is unusualto detect one event, I need to study a lot
09:54:21	25	of patients. If I want to see and if there's a background

		Ross - direct by Wisner
		1133
	1	rate to see if a drug is associated with that, I need to study
	2	even more patients.
	3	So the Paxil studies were never designed to look at
	4	that. The fact that they happened to find 5 suicides in the
09:54:43	5	original NDA compared to none for placebo is amazing. The fact
	6	that they had a huge increase in the odds ratio remember
	7	yesterday we were talking about suicide attempts and there was
	8	a statistically significant difference between Paxil and
	9	placebo, when the study was not designed to do that really
09:55:10	10	means there's a huge effect.
	11	Q. And does this so let's look at another table. This is
	12	for all adults for all ages, is that right, Doctor?
	13	A. That's correct.
	14	Q. And it also is for all types of psychiatric disorders, is
09:55:20	15	that right?
	16	A. Yes.
	17	Q. Okay. The FDA also did let me just find it really
	18	quickly.
	19	Did the FDA also do an analysis of the risk under 25?
09:55:38	20	A. It did.
	21	Q. All right. Let's
	22	A. Just to clarify, that is that analysis across all ages
	23	was for all drugs.
	24	Q. Yeah. And the Paxil-specific number, that relates to
09:55:52	25	Paxil, right?

		Ross - direct by Wisner 1134
	1	A. Correct.
	2	Q. So let's look at the table for just the under 25, okay
	3	Doctor.
	4	A. Yes.
09:55:58	5	Q. Do you see that?
	6	A. Yes.
	7	Q. Is that this is?
	8	A. Yes.
	9	Q. All right. And again now, this is limiting it to just
09:56:04	10	25, but does Paxil in any way stand out when it comes to the
	11	confidence interval?
	12	A. Yes.
	13	Q. How so?
	14	A. The confidence interval, again, is greater than or what
09:56:16	15	we call the lower bound.
	16	Q. And what is the odds ratio here?
	17	A. 2.23.
	18	Q. Now, the previous one was 2.76?
	19	A. Correct.
09:56:28	20	Q. So looking just at, you know, 18 to 25 year olds or under
	21	25, right, we have 2.33, is that what this saying?
	22	A. Correct.
	23	Q. Okay. And then when we expand it to the entire age group,
	24	the odds ratio actually increases to 2.76?
09:56:47	25	A. Right.

		Ross - direct by Wisner 1135
	1	MR. BAYMAN: Leading, Your Honor, objection.
	2	BY THE WITNESS:
	3	A. So if I can explain this
	4	THE COURT: Overruled. You may proceed.
09:56:56	5	THE WITNESS: I'm sorry, Your Honor.
	6	THE COURT: Go ahead.
	7	BY MR. WISNER:
	8	Q. Is that right? I'm going to ask you why in a second.
	9	A. Yes.
09:57:02	10	Q. What does that indicate to you?
	11	A. That there's an increased risk for older patients as well.
	12	And let me this is let me walk through this.
	13	If for all patients altogether the risk is increased
	14	and it's increased 176 percent. So that's how you get 2.76.
09:57:24	15	100 percent of the risk would be placebo, an additional 176
	16	percent would be what is added, and that gives you 276 or 2.76.
	17	So that's all ages.
	18	For younger individuals, that's actually their risk
	19	is 2.33, lower than 2.76. They actually have, compared to all
09:57:57	20	age group, they have an increased risk. And so this is all
	21	ages, 2.76.
	22	This is younger adults, 2.33. Therefore, people who
	23	are older than to bring this up when you add in those older
	24	patients, that risk must be actually higher than 2.76. The
09:58:19	25	younger adults actually have a lower risk than the older

1 adults, and then when you combine everything that brings the 2 older adults -- the risk that you see in older adults down. 3 I'm probably not explaining this as clearly as I might 4 be, but I hope people get the idea. If the risk in older 5 adults was normal, wasn't increased, and it's -- let's suppose 09:58:42 that this is placebo and this is younger adults (indicating), 6 7 and older adults are just the same as placebo. When you add 8 those older adults risk to the younger adults risk, the total risk should come down. 9 10 Just like if you're adding hot water, cold water into 09:59:05 11 hot water, the temperature should go down, but that didn't 12 happen here. You have as you go from younger adults to let's 13 say a certain temperature and then you add in the older adults, 14 the temperature actually goes up. 15 Q. And is it a reasonable inference from there that the risk 09:59:26 16 actually might be greater in adults over 25 than for adults or 17 people under 25? 18 A. That's the conclusion I would draw. Again, if it were 19 actually no risk or restricted, then the total risk should go down. You'd be, in essence, adding that cold water and 20 09:59:44 21 bringing that temperature down. 22 Did the FDA do an analysis just of 25 year olds to older? Q. In this document -- you're talking about for all drugs 23 Α. 24 altogether? 25 Q. Yeah. All drugs, all indications, but they just looked at 10:00:06

1136

		Ross - direct by Wisner
		1137
	1	above 25, not all ages. Did they do an analysis like that?
	2	A. I believe they did. I believe they did, but I don't
	3	remember seeing it in here.
	4	Q. Okay.
10:00:17	5	A. Which means I mean, when I say I mean that was not
	6	included in here, so
	7	Q. Oh, I see.
	8	A. I mean, there's a lot of times you'll do preliminary
	9	analyses and that sort of thing, but this is the final document
10:00:31	10	that is publicly available.
	11	Q. But you haven't seen
	12	A. And, no, I have not seen any such analysis. There are such
	13	analyses.
	14	Q. Well, did GSK actually do an analysis of suicidality or
10:00:43	15	suicidal behavior from people 25 and older?
	16	A. It did.
	17	Q. And did it publish those results in a journal?
	18	A. It did.
	19	Q. And what did they show?
10:00:52	20	A. They showed that the risk for Paxil compared to placebo in
	21	individuals older than 24, that is those aged 25 to 64, was
	22	actually increased, just as I was saying. It was not lower.
	23	Q. Was it higher than 2.76?
	24	A. Yes, it was.
10:01:13	25	Q. All right.

		Ross - direct by Wisner 1138
	1	Let's get to the label, Doctor. I have your marked up
	2	one and I have a blank one here. So what we're going to do is,
	3	I'm going to go through the label and I'm going to ask you
	4	questions about it and you're going to tell me what to do with
10:01:27	5	the markups, okay?
	6	A. Okay.
	7	MR. WISNER: Your Honor, permission to publish Joint
	8	Exhibit 1. It's in evidence.
	9	THE COURT: Yes.
10:01:39	10	(Exhibit published to the jury.)
	11	BY MR. WISNER:
	12	Q. Okay, Doctor, let's start off with what are we looking at
	13	here and what is this document?
	14	A. So I believe this is the label that was for Paxil that was
10:02:02	15	approved by the FDA on the basis of what GSK submitted at the
	16	time of Mr. Dolin's death.
	17	Q. All right. Let's just confirm that. Let's take a look at
	18	the last page here
	19	MR. BAYMAN: Excuse me. Could I see what he has?
10:02:19	20	MR. WISNER: Sorry, what?
	21	MR. BAYMAN: What he has in front of him. I just want
	22	to find out what he has in front of him.
	23	MR. WISNER: He doesn't have anything in front of him.
	24	He's got his binder.
10:02:25	25	MR. BAYMAN: I thought you have him a document.

		Ross – direct by Wisner 1139
	1	MR. WISNER: No; it's right here.
	2	MR. BAYMAN: All right. I thought you gave him the
	3	document.
	4	MR. WISNER: It's right here. I didn't teleport it up
10:02:31	5	there.
	6	BY MR. WISNER:
	7	Q. All right. So you see the data here, Doctor?
	8	A. Yes.
	9	Q. And that tells you what?
10:02:36	10	A. That tells me that this is a label that is current as of
	11	June 2010.
	12	Q. And do you see also that it has "GSK" right there on the
	13	logo, do you see that?
	14	A. Yes.
10:02:48	15	Q. Does that tell you that this is GSK's label?
	16	A. Yes.
	17	Q. All right. So a minute ago I asked you what's wrong with
	18	this label and you gave me two reasons basically why. What
	19	were those two reasons?
10:03:02	20	A. So first off, it restricts it does not include any
	21	information about Paxil inducing suicidal behavior, or worse,
	22	in adults 25 and older.
	23	Secondly, it talks about the risk for antidepressants,
	24	in general, being restricted to the age of 24 and under,
10:03:36	25	implying that that is true for Paxil as well.

		Ross - direct by Wisner
		1140
	1	Q. Okay, Doctor, in this label anywhere we're going to talk
	2	about what is in the label in a second, but I want to talk
	3	about what is not in the label.
	4	In this label is does it anywhere ever state in plain
10:03:56	5	English that Paxil can induce or can increase the risk of adult
	6	suicidal behavior in patients over the age of 24?
	7	A. No, it does not.
	8	Q. Okay. And if GSK had plainly said that somewhere in this
	9	label, do you believe they would have fulfilled the regulatory
10:04:16	10	obligations of warning physicians about a known safety risk?
	11	A. I'm sorry, if you can repeat the question.
	12	THE COURT: Read it back.
	13	(Question read.)
	14	BY THE WITNESS:
10:04:39	15	A. When you said "this information," the fact that it includes
	16	that it can induce suicidal behavior in adults older than
	17	24?
	18	BY MR. WISNER:
	19	Q. Yeah.
10:04:51	20	A. I'm going to qualify my answer in the sense that the
	21	language in the label would have to be such that that
	22	information was not diluted or minimized by something else. In
	23	other words, it's not individual statements, it's the whole
	24	context that one has to look at.
10:05:17	25	Q. All right, Doctor, we're sitting here staring at the label

		Ross - direct by Wisner 1141
	4	
	1	and the first thing we see is this black box; do you see that?
	2	A. Yes.
	3	Q. What is a black box?
	4	A. So the regulations actually this is not a random
10:05:33	5	document. There's actually a structure to it. And the
	6	structure it's like a book. It's like a story: How do I
	7	use this drug. You describe the drug, you say what happens
	8	when it goes in the body, how does it get absorbed, what can it
	9	be used for, what sort of things you have to worry about when
10:05:55	10	you give it to patients, who should you never, ever, ever give
	11	it to, who do you have to be careful about giving it to.
	12	And so there's sections like description, precautions,
	13	indications and usage, dosage. There's a section called
	14	"warnings." And sometimes the warnings are so important that
10:06:17	15	the regs allow for them to be put at the very top in what's
	16	called a black box warning.
	17	Q. In your opinion and as regulatory expert, is the placement
	18	of a warning in the black box make it the most prominent piece
	19	of information on the label?
10:06:37	20	A. Yes.
	21	Q. All right. Now, let's start off with the black box
	22	warning.
	23	Is there anything in this black box warning that, in
	24	your opinion, is misleading as it applies specifically to
10:06:50	25	Paxil?

		Ross - direct by Wisner 1142
	1	A. Yes.
	2	Q. Please read to the jury, I'll zoom a little bit so we can
	3	walk through this, please tell me the part, Doctor, that you
	4	believe is.
10:07:02	5	A. So the most misleading part, if we can begin on the fifth
	6	line. If you could just highlight that.
	7	Q. Sure. Is red ink okay?
	8	A. Yes.
	9	Q. So tell me what to underline.
10:07:24	10	A. So beginning with "short-term studies."
	11	Q. Just tell me what they are.
	12	A. (Reading:)
	13	"Short-term studies did not show an increase in
	14	the risk of suicidality" which means suicidal
10:07:35	15	behavior and worse " with antidepressants
	16	compared to placebo in adults beyond age 24."
	17	Q. Okay, Doctor, is that an accurate statement as it relates
	18	to Paxil?
	19	A. No.
10:07:52	20	Q. How so?
	21	A. The increased risk in the increase in risk in suicidal
	22	behavior for Paxil goes to all ages. Across all ages, as we're
	23	talking about a few minutes ago, it's 2.76.
	24	Q. And it goes on to say:
10:08:18	25	" there was a reduction in risk with

		Ross - direct by Wisner 1143
	1	antidepressants compared to placebo in adults
	2	aged 65 and older."
	3	What does that suggest to a physician reading it?
	4	A. If
10:08:32	5	MR. BAYMAN: Objection, Your Honor, what is suggest to
	6	a physician reading it.
	7	THE COURT: Overruled. As an expert he can express
	8	his opinion on that subject.
	9	BY THE WITNESS:
10:08:41	10	A. If you're saying the risk is here for young people and it
	11	gets lower for older individuals, the suggestion is going to
	12	be, well the risk goes down as you get older, and that's not
	13	true for Paxil.
	14	BY MR. WISNER:
10:08:55	15	Q. In fact, if we look at the sentence before that, Doctor,
	16	what does that say?
	17	A. It's saying:
	18	" anyone considering the use of Paxil or any
	19	other antidepressant in a child, adolescent or
10:09:10	20	young adult must balance this risk with the
	21	clinical need."
	22	Q. What is your understanding of what this black box warning
	23	is telling physicians to be careful of?
	24	A. Use of any antidepressant. And just to be clear, this is a
10:09:24	25	template. If you were to go to another SSRI, for example,

		Ross - direct by Wisner
		1144
	1	let's take, I don't know, Prozac, it would simply substitute in
	2	the word "Prozac."
	3	Q. You mean right here with "Paxil"?
	4	A. Correct. So that is not specific information that is
10:09:45	5	unique to Paxil. You would see that in any other SSRI.
	6	Q. All right. So I'm going to stop right there. In your
	7	expert opinion, is this false or misleading?
	8	A. Yes.
	9	Q. Would it be okay if I wrote "false" right here?
10:10:01	10	A. Yes.
	11	Q. All right.
	12	And I'll say for Paxil.
	13	A. Actually if I could, I would say false and misleading, but
	14	in the interest of time
10:10:16	15	Q. Okay. All right. So it goes on to say:
	16	" depression and certain our psychiatric
	17	disorders are themselves associated with
	18	increases in the risk of suicide."
	19	Now, Doctor, is that a warning at all?
10:10:30	20	A. No.
	21	Q. What would you call that?
	22	A. That is what I'd call advise in taking care of patients,
	23	what we call disease management.
	24	Q. I'm going to add "misleading" here because I don't want to
10:10:44	25	make it seem like I'm saying anything.

		Ross - direct by Wisner 1145
	4	
	1	(Brief pause).
	2	BY MR. WISNER:
	3	Q. All right. So you said disease management. What is
	4	disease management, Doctor?
10:10:56	5	A. So that's basically the details of how we take care of
	6	patients. Depression can get worse and lead to suicide, that's
	7	one depression by itself, even if it doesn't get worse, is
	8	an extremely serious condition. Can lead to all sorts of
	9	problems besides suicide, but suicide, as I said in my report,
10:11:20	10	is the most extreme consequence of depression.
	11	So you that's something you'd see in a medical
	12	textbook. It has nothing to do with drug risks, per se.
	13	Q. By focusing in the label on how the underlying disease can
	14	cause a risk, does that take away from the potential additional
10:11:43	15	risk potentially caused by the drug?
	16	A. Yes.
	17	Q. And, in your opinion, with a statement like depression and
	18	certain other psychiatric disorders are themselves associated
	19	with increases in the risk of suicide, does that create any
10:11:58	20	obligation on GSK to focus specifically on the risks associated
	21	with Paxil?
	22	A. Could I hear the question one more time?
	23	THE COURT: Read it back.
	24	(Question read.)
10:12:27	25	BY THE WITNESS:

		Ross - direct by Wisner 1146
	1	A. Well, it doesn't I would say that it doesn't address the
	2	responsibility. It doesn't talk about the risk associated with
	3	Paxil. It's talking about the risk associated with the
	4	disease.
	5	BY MR. WISNER:
10:12:41	6	
		Q. And you characterize that as disease management?
	7	A. Yes.
	8	Q. Do you believe statements in a label that relate to disease
	9	management qualify as a warning about a risk for a drug?
10:12:52	10	A. No.
	11	Q. All right. So we're in the black box still. And it says:
	12	" patients of all ages who are treated on an
	13	antidepressant therapy should be monitored
	14	appropriately and observed closely for clinical
10:13:07	15	worsening, suicidal, or unusual changes in
	16	behavior."
	17	That sentence which follows a statement that
	18	depression itself increases the risk of suicidality, how would
	19	you characterize that?
10:13:18	20	A. That is disease management.
	21	Q. All right. Keep going:
	22	" families and caregivers should be advised of
	23	the need for close observation and communication
	24	with the prescriber. Paxil is not approved for
10:13:28	25	use in pediatric patients."

		Ross - direct by Wisner 1147
	1	Other than that last sentence, Paxil is not approved
	2	for pediatric patients, what is that sentence with families and
	2	caregivers, what is that?
	4	A. It's good advise, but it has no connection with informing
	4 5	
10:13:45		prescribers or patients about the risk of a drug.
	6	Q. Does this black box anywhere state, in simple and bolded
	7	language, that Paxil increases the risk of adult suicidal
	8	behavior over the age of 24?
	9	A. No.
10:14:02	10	Q. What does it say?
	11	A. About that particular risk?
	12	Q. Yes.
	13	A. Nothing.
	14	Q. What does it say about underage, beyond the age of 24?
10:14:15	15	A. It's silent on that with respect to Paxil. It just says,
	16	as a group, antidepressants the risk of suicidality
	17	associated with antidepressants is just 24 and under.
	18	Q. So that statement about Paxil-specific language, reading
	19	this does this suggest that the risk for Paxil and suicidality
10:14:41	20	does not extend beyond the age of 24?
	21	A. It does.
	22	Q. And this is in the first paragraph of the label?
	23	A. Not just the first paragraph; the most prominent portion of
	24	the label.
10:14:52	25	Q. All right. Could GSK have added or could have requested to

		Ross - direct by Wisner 1148
	1	add that statement, that Paxil could increase the risk of adult
	2	suicide or behavior over 24?
	3	A. Yes.
	4	Q. All right. Where could they have requested to put it?
10:15:10	5	MR. BAYMAN: Your Honor, objection. This is a totally
	6	new opinion. He was asked this question at the depression and
	7	he said he didn't have an opinion about where else it should go
	8	in the label. It's not in his report and we object that this
	9	is outside the scope and this is a violation of the Rule 26(e)
10:15:27	10	of the duty to supplement the expert report with new opinions.
	11	MR. WISNER: Your Honor, he clearly stated in his
	12	report, as well as during his depression, that they could've
	13	put it anywhere outside of the class labeling, and that's
	14	exactly what he's testifying to right now.
10:15:39	15	THE COURT: He may testify.
	16	BY THE WITNESS:
	17	A. Thank you, Your Honor.
	18	So the regulations are pretty general about what
	19	should go in. And it says, for example, under
10:15:58	20	"contraindications," these are population of patients who
	21	should not get the drug, but it doesn't go into a whole lot
	22	more detail.
	23	So this give both manufactures and the FDA a lot of
	24	flexibility. And there's a whole part of FDA that's concerned
10:16:18	25	with risk communication. How do we best inform prescribers and

	1	patients about what the risks are.
	2	So having said that, there's a large number of areas
	3	in the label, in different sections, where this information not
	4	only could go but should go. The only one, I just want to
10:16:43	5	address this up front, that the FDA said "we don't want it in
	6	this section" is in the exact middle of the class labeling, but
	7	that's the only thing they said "no" to. They didn't say we
	8	don't want it anywhere in the label. So starting out with a
	9	black box
10:17:06	10	BY MR. WISNER:
	11	Q. I'm going to stop you right there, Doctor, before we move
	12	off the topic.
	13	A. Yes.
	14	Q. I want to be very clear, did GSK ever attempt to put the
10:17:13	15	statement that Paxil induces the risk of adult suicidal
	16	behavior over the age 24 anywhere in the label?
	17	A. No.
	18	Q. Okay. Sorry, you were explaining about the black box. I
	19	wanted to make sure it didn't get lost.
10:17:27	20	A. No. No. They didn't.
	21	So let me just walk through this. There's no reason,
	22	except the FDA said, well, we don't want it in the middle.
	23	Okay, it could've gone at the end of this (indicating).
	24	MR. BAYMAN: Objection, Your Honor. Again, this is a
10:17:46	25	new opinion. May I have a continuing objection?
		1

		Ross - direct by Wisner 1150
	1	THE COURT: Yes, you may.
	2	MR. BAYMAN: Thank you.
	3	BY MR. WISER:
	4	Q. So you said right here at the end (indicating)?
10:17:53	5	A. Yes.
	6	Q. Can I draw an arrow?
	7	A. Sure.
	8	Q. All right. So what I'm going to do with my terrible
	9	handwriting is try to keep a counting of all this. So I'm
10:18:04	10	going to put number 1 here, all right?
	11	A. Okay.
	12	Q. So they could've put it right here at the end of the class
	13	portion of the black box warning, is that right?
	14	A. Yes.
10:18:13	15	Q. All right. Could they put it somewhere else?
	16	A. Yes, they could've put it immediately below the black box
	17	warning.
	18	Q. And if you want to point to it on the screen, Doctor. I
	19	think it's actually touch-sensitive.
10:18:29	20	A. This is what happens when you get too highly specialized.
	21	I'm sorry, I'm touching it but
	22	Q. Just underline it.
	23	A. Okay.
	24	Q. Perfect.
10:18:40	25	So right here (indicating) then?

		Ross - direct by Wisner 1151
	1	A. Yes.
	2	Q. Okay. Great. All right. So now we've and I'll clear
	3	it each time so we can keep ourselves on track here.
	4	All right. So we have it now just above the
10:18:54	5	description. And do you think it would've been smart, from a
	6	regulatory perspective, to put this risk right smack on the
	7	first page just before you get into all the nitty-gritty of the
	8	1abe1?
	9	A. Yes.
10:19:05	10	Q. Why is that?
	11	A. This is except for we used to say the FDA, except for
	12	the nerds who are looking at that chemical structure
	13	immediately below, most physicians are going to look at two
	14	things, the warnings and how much do I give.
10:19:28	15	Q. All right. So we go into the description section. Is this
	16	the area that you would've suggested that they put a suicide
	17	warning for adults over 24?
	18	A. In clinical pharmacology information?
	19	Q. Yes.
10:19:45	20	A. No.
	21	Q. So we're going to go to the next section after clinical
	22	pharmaceutical, and now we're here in this section entitled
	23	Clinical Trials; do you see that, Doctor?
	24	A. Yes.
10:19:55	25	Q. All right. Do you have an opinion about this?

		Ross - direct by Wisner 1152
	1	A. Yes.
	2	Q. What's your opinion?
	3	A. So the clinical trial section gives the actual or
	4	summary of the actual information that the FDA has relied on in
10:20:07	5	approving the drug.
	6	And in this instant incidence there was clinical
	7	trial I'm sorry, clinical trial data across all indications,
	8	as well as trials for Paxil and depression showing an increased
	9	risk of suicidal behavior.
10:20:27	10	So you certainly could logically say, since it's
	11	across all indications, and the clinical trials go over the
	12	various indications that were studied, you could put it right
	13	here (indicating).
	14	Q. Okay.
10:20:46	15	A. So it's the first thing to say because that was the
	16	result where you combined trials for all indications.
	17	Q. Okay. Great. Where else could you put it?
	18	A. Well, certainly look at major depressive disorder,
	19	specifically you could put it here (indicating) or you
10:21:05	20	certainly could put it just to be clear, number 3, that
	21	would be this is a general warning or general indication
	22	about the risk, that 2.76 here (indicating). If you were
	23	looking specifically at major depressive disorder, you could
	24	put it at the beginning or at the end.
10:21:28	25	Q. So what I'll do is I'll put it in here and put "4" and then

		Ross - direct by Wisner 1153
	1	draw an arrow up, is that fair?
	2	A. Yes.
	3	Q. Let's keep moving on. We got Obsessive Compulsive
	4	Disorder, Panic Disorder, do you see that, Doctor?
10:21:46	5	A. Yes.
	6	Q. Okay. All right. Social Anxiety Disorder. Do you know
	7	have you seen any studies, clinical studies that focused on any
	8	of these specific indications other than MDD?
	9	A. I have seen clinical studies but not analyses that
10:22:04	10	specifically address the suicide risk on the way they have for
	11	MDD.
	12	Q. Okay. All right. We got Post-Traumatic Stress Disorder.
	13	Now, we're in "indications and usage," do you see that, Doctor?
	14	A. Yes.
10:22:20	15	Q. We're on page 8 of Joint Exhibit 1.
	16	What, if anything, could go in here?
	17	A. So this so just to be clear, "Indications and Usage"
	18	goes to what conditions the drug has been studied in and for
	19	which there is evidence, what I'll call substantial evidence of
10:22:48	20	efficacy, but it's not just the diseases, it's also the
	21	populations. So, for example, kids are considered a different
	22	population than adults.
	23	Q. So this is more for efficacy, is that right?
	24	A. Yeah.
10:23:00	25	Q. So you wouldn't put a suicidal warning for adults over 24?

		Ross - direct by Wisner 1154
	1	A. No. No.
	2	Q. All right. Post-Traumatic Stress. So let's go through the
	3	whole section.
	4	All right. Now we're in the warnings, do you see
10:23:15	5	that, Doctor?
	6	A. Yes.
	7	Q. All right. What is the warnings section and do you believe
	8	that there could've been a warning about adult suicidal
	9	behavior over the age of 24 in the warnings?
10:23:24	10	A. Yes. So the warnings section warns about side effects that
	11	are particularly severe, even fatal.
	12	Q. All right. So where would you put it?
	13	A. So, again, there are multiple areas where this could go.
	14	And again, the goal is not to so much to just to obey the
10:23:46	15	regulations, although that is obviously critical, we want to
	16	tell people about what's going on. And I rely on these labels
	17	when I'm prescribing. So you could put it before everything
	18	else.
	19	Q. So right here before the class labeling, right?
10:24:04	20	A. Yes.
	21	Q. Now, actually I just ask to clarify. There's a section
	22	that says "Clinical Worsening and Suicide Risk," do you see
	23	that?
	24	A. Yes.
10:24:10	25	Q. And it extends to this page, has a chart up here, and then

		Ross - direct by Wisner 1155
	1	it goes down to this page, and then it ends on this page
	2	(indicating)?
	3	A. Yes.
	4	Q. Okay. So all that class-wide warning, is that specific to
10:24:27	5	Paxil?
	6	A. None of it is.
	7	Q. What is it specific to?
	8	A. It addresses the general issue of suicidal behavior in
	9	patients on antidepressants.
10:24:36	10	Q. And this was the class warning that was focused on under
	11	25 years old?
	12	A. Yes.
	13	Q. So it could've gone right here (indicating). Where else
	14	could it gone, Doctor?
10:24:48	15	A. So actually before I get to that, one other very important
	16	point: I mentioned that there are circumstances in which a
	17	manufacturer can go ahead and add or strengthen a warning
	18	without getting prior clearance from the FDA; this is a section
	19	where you can do that.
10:25:05	20	Q. So you're telling me, without getting prior approval from
	21	the FDA, GSK said right here, under the warning section, this
	22	drug induces suicidal behavior in adults over 24?
	23	A. That's correct.
	24	Q. Have you seen any evidence or any submissions by GSK that
10:25:24	25	they ever tried to do that?

		Ross - direct by Wisner 1156
	1	A. Not in a way that I would regard well, let me put it
	2	like this, you asked if they had added that information earlier
	3	if they would have made it not false or misleading and I said
	4	no. They had added information
10:25:39	5	Q. Doctor
	6	A. I'm sorry.
	7	Q I don't want to get into that conversation.
	8	A. Okay.
	9	Q. I want you to focus on my question.
10:25:48	10	My question was, have you seen any evidence
	11	A. No.
	12	Q. Hold on. Let me ask the question.
	13	A. I'm sorry.
	14	Q. Have you seen any evidence that GSK tried to put a
10:25:57	15	statement that Paxil induces the risks of adult suicidal
	16	behavior over 24 in this part of the label?
	17	A. I apologize for assuming. No, they have not.
	18	Q. Again to clarify, have they ever made that proposal
	19	anywhere in the label?
10:26:14	20	A. No.
	21	Q. All right. So we got the warning section here. And do you
	22	think it would've been appropriate from a regulatory
	23	perspective, and as a clinical practitioner, as a physician, to
	24	put that suicide risk as it relates to Paxil smack at the
10:26:34	25	beginning of the warning section?

		Ross - direct by Wisner 1157
	1	A. Yes.
	2	Q. Why?
	3	A. That is the most prominent place. I mean, you're talking
	4	about a long, intense label. In the first, it makes it more
10:26:43	5	likely that people are going to see it.
	6	Q. All right. So then we get into the class-wide warning. Do
	7	you see this whole section, Doctor?
	8	A. Yes.
	9	Q. And you mentioned earlier that GSK would not have been
10:26:52	10	allowed to put it in the middle of any of these paragraphs, is
	11	that right?
	12	A. Correct.
	13	Q. Could they have put it at the beginning of it?
	14	A. Yes.
10:27:01	15	Q. Do you have an opinion about whether or not GSK could've
	16	or, quite frankly, should have put in a warning about adult
	17	suicidal risk for Paxil over 24 in the clinical worsening
	18	suicide risk section?
	19	A. I think they absolutely could have, should have, and could
10:27:23	20	have done it without getting prior approval.
	21	Q. Okay. And so could you mark on the screen where you think
	22	it could have gone? At the beginning, I assume?
	23	A. Yes.
	24	Q. All right. So I guess right after the colon, so right here
10:27:34	25	(indicating). And I'll call it number 6, okay?
		1

		Ross - direct by Wisner 1158
	1	A. Yes.
	2	Q. And then separately, I'm going to go to the end of the
	3	class warning.
	4	A. Before you do that, could I just add one comment here?
10:27:46	5	Q. Sure.
	6	A. If you go to down to the second paragraph, and I'll just
	7	I don't want to mark up the screen, but on the 2, 3, 4, 5, on
	8	the 6th line of that paragraph "there was considerable
	9	variation in risk of suicidality among drugs."
10:28:01	10	Q. Yes.
	11	A. So what that doesn't say is when they say variability,
	12	they mean that you've got a drug like Paxil with a very high
	13	risk with a confidence interval that shows that we know that
	14	that is real, but it doesn't mention that. It just is sort of
10:28:29	15	like language, but that is the underlying thing and does not
	16	by not having that information there, that 2.76, that is
	17	misleading.
	18	Q. In your opinion, Doctor, this statement that there was
	19	considerable variation of risk among drugs, without having any
10:28:51	20	Paxil-specific information, does that cause problems?
	21	A. Yes.
	22	Q. Okay. Would you like me to underline that, because you
	23	pointed it out.
	24	A. Please.
10:29:00	25	Q. In red?

		Ross - direct by Wisner 1159
	1	A. Please.
	2	Q. All right. So there was considerable variation in risk
	3	among drugs with
	4	Is that it, Doctor?
10:29:11	5	A. Yes.
	6	Q. Okay. Great. Okay. And, quite frankly, we're actually
	7	going to go into this in a minute and go trough the class
	8	warning, I just want to get to the places where they could've
	9	warned. We're talking about what they haven't done and then
10:29:25	10	we're going to talk about what they did do, okay?
	11	A. Okay.
	12	Q. All right. So this is the class warning, right. And you
	13	would agree they couldn't put it in the middle of any of this,
	14	right?
10:29:32	15	In the middle of any of this?
	16	A. Yes.
	17	Q. All right. All this stuff keeps going. And we're going to
	18	talk about that that says in just a minute, Doctor. And then
	19	we get to the end of the class warning right here, before
10:29:40	20	screening patients?
	21	A. Yes.
	22	Q. Do you have an opinion about whether or not GSK could've
	23	added Paxil-specific language here?
	24	A. Yes.
10:29:56	25	Q. What's your opinion?

		Ross - direct by Wisner 1160
	1	A. It could have.
	2	Q. Okay. Where? Could you point on the screen.
	3	A. So it could've gone right here (indicating) after the class
	4	labeling.
10:30:06	5	Q. So right there, Doctor (indicating)?
	6	A. Yes.
	7	Q. Sorry.
	8	A. My drawing is not too good these days. I mean, it really
	9	could come it's
10:30:18	10	Q. Let me clear it.
	11	A. Yeah. So as long as it did not go in the middle of the
	12	class labeling section. It could go before, it could go after.
	13	Q. All right. So why don't we put the arrow. Right here
	14	(indicating).
10:30:34	15	What number are we at, do you know? 7?
	16	(Brief pause).
	17	BY MR. WISNER:
	18	Q. All right. And then moving through this warning section,
	19	it keeps going, it has all these different warnings, could GSK
10:30:44	20	have put a warning section in after the class-wide warning in a
	21	separate section for Paxil?
	22	A. Yes.
	23	Q. All right. So then for the 7, how should I represent that
	24	on this? You tell me.
10:30:56	25	A. I think you could just draw an arrow down through this

		Ross - direct by Wisner 1161
	1	entire warning section and say it could have gone you know,
	2	a separate section could have gone anywhere under the
	3	regulations.
	4	Q. All the way down here (indicating).
10:31:10	5	Is that right?
	6	A. No, I would not put it in the pregnancy section, obviously,
	7	but, you know, it would be I think as a separate section it
	8	could go, you know, in someplace where it's not a subhead under
	9	another.
10:31:31	10	Q. So, for example, slide it in right there (indicating)?
	11	A. Right.
	12	Q. Okay. So I'm going to keep going through this. We're on
	13	the next page. It keeps going.
	14	All right. Now, we get to precautions. Just to be
10:31:51	15	clear, we just went through all those different sections and
	16	the warning, and we're going to go into more detail in class
	17	portion in just a second
	18	A. Uh-huh.
	19	Q but do you recall whether or not GSK requested or even
10:32:07	20	attempted without prior approval to put a warning about
	21	Paxil-induced suicidal behavior in adults over 24 in the entire
	22	section for warnings?
	23	MR. BAYMAN: Your Honor, this has been asked about 3
	24	or 4 times now.
10:32:21	25	THE COURT: I think it's covered.

		Ross - direct by Wisner 1162
	1	MR. WISNER: Okay.
	2	THE COURT: Proceed.
	3	MR. WISNER: Fair enough, Your Honor.
	4	BY MR. WISNER:
10:32:43	5	Q. I want to make sure I get the record clear. So you said it
	6	wouldn't go in the pregnancy three, do you recall that?
	7	A. Yes.
	8	Q. All right. I'm going to mark it again so there's actually
	9	a record of it because the screen gets cleared and you don't
10:32:48	10	see it.
	11	So it was right here is the arrow that we pointed to,
	12	is that right?
	13	A. Yes.
	14	Q. Okay.
10:33:14	15	(Whereupon, there was a conference had between
	16	counsel off the record).
	17	BY MR. WISNER:
	18	Q. Okay, Doctor, I want to clarify. When you have this arrow,
	19	it keeps going, an arrow down like that (indicating). Just to
10:33:24	20	clarify, you mean it can go in the pregnancy or does that have
	21	to go before or after?
	22	A. It would have to go before or after.
	23	Q. Okay. And so for all of these folded sections, is that
	24	what you're referring?
10:33:33	25	A. Correct. It would not go

		Ross - direct by Wisner 1163
	1	Q. Right here, for example, on page 13 (indicating)?
	2	A. Correct. And, for example, there's things about animal
	3	effects, you know, it would have to go outside one of these
	4	sections with it would be a section that would have one of
10:33:48	5	these kind of headings like potential for interaction with
	6	monoaminoxidase inhibitors.
	7	Q. Okay. So I'll do another section like there here,
	8	serotonin syndrome, do you see that?
	9	A. Yes.
10:34:02	10	Q. Now is that a different font or color?
10.34.02	11	No, it's the same. Okay. Just bad lighting from
	12	here.
	13	So to be clear, it could be any of these sections? I
	14	just want to make sure the record is clear.
10:34:17	15	A. Yes.
10:34:17	16	Q. All right. Okay. Now to the precautions section.
	17	A. Yes.
	18	Q. What's the difference between a warning and a precaution?
	19	A. So a precaution is just what it sounds like, a section
10:34:36	20	where you say certain things might happen during treatment and
	21	here's the rate at which they happen.
	22	So, for example, under seizures, one out of 1,000
	23	pages got seizures. Paxil should be used cautiously in
	24	patients with a history of seizures. But here you're getting
10:35:03	25	kind of more detailed information about things to be careful

		Ross - direct by Wisner 1164
	1	about specifically with this drug.
	2	Q. All right. And, again, do you have an opinion about
	3	whether or not GSK could've requested to put an adult specific
	4	warning over 25 in the precaution section?
10:35:25	5	A. Yes.
	6	Q. What's your opinion?
	7	A. My opinion is that it certainly it could've and would've
	8	made complete sense to do that.
	9	Q. Okay. So where would you put it?
10:35:37	10	A. I would put it at the beginning.
	11	Q. So right under "precautions"?
	12	A. Yes.
	13	Q. Okay. All right. And anywhere else you could've put it?
	14	A. In precautions? I mean, it really can go anywhere in this
10:35:58	15	section. I think the most logical place would be at the
	16	beginning, but you could simply create I mean, you could put
	17	it under you could put it anywhere. I think the most
	18	logical place would be at the beginning to increase its chances
	19	that the prescribers and patients are going to see it.
10:36:17	20	Q. All right. Let's move to the precaution sections. And
	21	let's talk for a second, because I know this is going to come
	22	up at some point, see this sentence where it says "akathisia"?
	23	A. Yes.
	24	Q. All right. Anywhere in this akathisia warning, does it
10:36:35	25	relate akathisia to suicidal behavior?

		Ross - direct by Wisner 1165
	1	A. No.
	2	Q. Do you think that's a problem?
	3	A. Yes.
	4	Q. Why?
10:36:43	5	MR. BAYMAN: Your Honor, again objection. He's not
	6	expressed an opinion on this in his report, in his deposition
	7	testimony, and it's not been supplemented. So we object to
	8	this entire line.
	9	MR. WISNER: In his report he does discuss akathisia.
10:36:57	10	MR. BAYMAN: It's not an opinion about what should in
	11	the label about it.
	12	THE COURT: You may proceed.
	13	MR. WISNER: Thank you, Your Honor.
	14	MR. BAYMAN: Continuing objection to this line, Your
10:37:07	15	Honor.
	16	THE COURT: Yes.
	17	MR. BAYMAN: Thank you.
	18	BY MR. WISER:
	19	Q. So what's the problem of this akathisia discussion not
10:37:12	20	including a discussion about suicide?
	21	A. Well, it doesn't say that akathisia is not just some funny
	22	word. It is something that is associated with suicidal
	23	behavior.
	24	If I can just go to the section right below it and
10:37:36	25	just to contrast this?

		Ross - direct by Wisner 1166
	1	Q. Sure.
	2	A. So it's talking about the possibility that SSRIs can lead
	3	to hyponitremia, which is just low sodium in the blood, and it
	4	says cases with serotonin sodium lower than 110 millimeters
10:37:53	5	have been reported. Normal sodium is like 145.
	6	Q. This line right here (indicating)?
	7	A. Yes, I'm sorry. At 110, any physician, general internist,
	8	primary care physician, certainly a psychiatrist would say,
	9	whoa, that is a life threatening level. The significance of
10:38:17	10	that is pretty clear, it's a basic thing in medicine.
	11	Akathisia would not be and, therefore, this is where you got to
	12	spell it out.
	13	Q. Well, I see under how do you say that hypo
	14	A. Hyponatremia.
10:38:35	15	Q. Okay, hyponatremia. It says here at the bottom, do you se
	16	it says "death"?
	17	A. Yes.
	18	Q. Is there any statement in akathisia about that leading to
	19	death?
10:38:41	20	A. No.
	21	Q. Is that a problem?
	22	A. Yes.
	23	Q. All right. Do you have an opinion about whether or not in
	24	this portion of the label with regards to akathisia, GSK
10:38:53	25	could've put information?

		Ross - direct by Wisner 1167
	1	A. Not just could've but should've.
	2	Q. And where would that have gone or could've gone?
	3	A. I think you could put that at the end and say for
	4	example, and say "akathisia is associated with suicidal
10:39:16	5	behavior and this is data that the company has published."
	6	Most suicides happen early on, that are induced by Paxil,
	7	happen early on in treatment.
	8	Q. Okay. So here's another place they could've added
	9	something.
10:39:32	10	All right. Let's keep going through the label here.
	11	You mentioned that all right. So here we go. There is a
	12	section here, Doctor, that says "clinical worsening in suicide
	13	risk," do you see that?
	14	A. Yes.
10:39:55	15	Q. All right. Is this actually the same warning that's in
	16	every antidepressant?
	17	A. Yes.
	18	Q. Okay. Can you just tell me what, if anything do you
	19	have an opinion about whether or not GSK should've added
10:40:04	20	anything to this section?
	21	A. Well, again, this is disease management. And it's fine as
	22	far as it goes. I mean, there's nothing wrong with it, but it
	23	has to do with taking care of patients with depression in
	24	general, not with the risks of the drug. It doesn't say
10:40:20	25	there's something unique about Paxil in terms of the data we

		Ross - direct by Wisner 1168
	1	have available, that's just not in there. So
	2	Q. So
	3	A. Go ahead.
	4	Q. So, Doctor, it says here:
10:40:33	5	"Patients their families and their caregivers
	6	should be encouraged to be alert"
	7	and it lists all these different things:
	8	" worsening in depression and suicidal
	9	ideation especially during antidepressant
10:40:46	10	treatment and when the dose is adjusted up or
	11	down."
	12	Does that say anything that the drug itself is
	13	causing suicidal behavior?
	14	A. No.
10:40:53	15	${\tt Q}$. Is that a statement or is that an instruction of how to
	16	practice medicine?
	17	A. It's it's really about, I would say, disease management
	18	in the sense of what kind of discussion do you have with
	19	patients.
10:41:11	20	Remember, when I describe something, it's not just an
	21	order, here take this. I sit down and I say, here's the pros,
	22	here's the cons, here's what could happen. And if there's a
	23	member in the family in the room I'm going to talk to them too.
	24	If there's something where you know, like I think something
10:41:33	25	might happen that I want to call out to them, then this gives

		Ross - direct by Wisner
		1169
	1	me guidance on what to do, but this has nothing specific about
	2	Paxil.
	3	Q. So to be clear, Doctor, if you have a patient that's
	4	depressed, and let's say you're not giving them an SSRI at all,
10:41:50	5	what conversation do you have with them about paying attention
	6	to clinical worsening and depression and suicide?
	7	A. Well, that things can get worse quickly. That they you
	8	know, this is not don't be afraid of calling me, don't be
	9	afraid of calling the emergency room. But people's threshold
10:42:14	10	for I mean, they're not, you know, going to know necessarily
	11	is this worse or not if they know something specifically like
	12	this really might increase the risk of this happening.
	13	Q. We're talking about a person that you're not prescribing
	14	A. That I'm not prescribing I'm sorry.
10:42:33	15	Q. Do you talk about watching out for suicidality because
	16	they're depressed?
	17	A. Yes. Yes. And, I mean, that's one thing, if somebody
	18	one thing as a matter of course that's done, not just for me,
	19	I'm not trying to say, you know, I'm perfect, but this is
10:42:45	20	actually done in my health core organization, the system
	21	prompts' providers to ask on a regular basis about depression
	22	specifically. And if what we call the score of depression
	23	symptoms is high, you would ask more questions. And if that's
	24	positive, do something, don't just stand there. So that's just
10:43:12	25	the sort of general procedure, and I work with a population

1 that is at a high risk for depression.

2 Q. How does the conversation change when you're talking to 3 someone who has depression and there's obviously a risk of 4 suicide associated with depression, how does that change when 5 you say in addition to depression, we have this other risk, SSRIs? How does that change? 6

7 A. Well, I want to let them know not only that such might happen, but what it's due to and what to do about it. And it's 8 -- it's -- it's a conversation. It's not simply my lecturing 9 10 them, the patient. So I might say, you know, I'm thinking 10:43:55 11 about -- and I do this all the time in terms of other classes of drugs, I'll say, well, here's what I'm thinking about this 12 drug. And the patient will say, well, how many times a day do 13 14 I have to take it; once; great. Or this might give you trouble 15 sleeping, it might give you weird dreams; well, I'm not sure I 16 really like that.

> 17 So if I'm saying this is not just a discussion about 18 what to do when you're prescribing it, it's also starting it. 19 So if I say, well, this drug has an increased risk of inducing 20 suicidal behavior, a patient might very well say, well why are 21 you giving it to me. And I might say, you know, that's a good 22 question. Or I might say, you know, it's a risk, we know it's 23 a risk, but I don't have any other alternatives.

24 But that's a discussion, but certainly the patient 25 needs to know, because really we're talking about informed 10:44:54

10:44:16

10:43:31

- 10:44:35

		Ross - direct by Wisner 1171
	1	consent for treatment.
	2	Q. If you don't know that the drug can cause already depressed
	3	people to become more suicidal, can you have that discussion?
	4	A. No.
10:45:10	5	Q. Okay. So back to this portion of the label that talks
	6	about being alert to anxiety and suicidality. You said this is
	7	disease management, is that right?
	8	A. Yes.
	9	Q. Now, would this warning or this discussion about disease
10:45:24	10	management shift if before it starts talking about patients it
	11	said "Paxil induces the risk of suicidal behavior in adults
	12	over 24," how does that change the caricature of this warning?
	13	A. It gives me more information that I can provide to the
	14	patient well, first off, that I can take into consideration
10:45:45	15	myself. I mean, we're talking about the patient section, and
	16	more information I can give the patient.
	17	Q. Now, to be clear, do you have an opinion about where in
	18	this clinical worsening in suicide risk section GSK should have
	19	discussed Paxil specifically inducing suicidal behavior?
10:46:07	20	A. I really think at the beginning.
	21	Q. So right here (indicating)?
	22	A. Yes.
	23	Q. What number are we at, Doctor, do you recall? Number 10?
	24	A. 10, yes.
10:46:21	25	Q. And while we're here, I just want to be clear. This

section about clinical worsening and suicide risk, this disease
 management language, has that been in the label since the
 beginning?

10:46:39

10:47:00

10:47:22

10:47:40

A. There has been all along, going back to earlier classes of
antidepressants, this kind of I don't want to say boilerplate
because it does mean something, but disease management.

I mean, if you go back, for example, there's a section
that said, under warnings, Paxil, you should prescribe the
fewest number -- the lowest number of tablets of Paxil that you
can in this, and that's something that was written down in the
labels for the older antidepressants like tricyclics. So this
is nothing new.

Q. And if a person has been using labels for antidepressants,
SSRIs, from the beginning, from the '90s onward, does this give
you any new information about whether or not Paxil itself

16 induces suicidal behavior over 24?

17 A. No.

18 Q. All right. So we have a bunch of other stuff here. We
19 have stuff about, you know, alcohol and pregnancy and nursing,
20 do you see that, Doctor?

21 A. Yes.

22 Q. Do you think a suicidal warning goes into any of these type23 of things?

A. It could be a separate section in here. Again, I would put
10:47:51 25 it up at a -- at the beginning.

1172

		Ross - direct by Wisner 1173
	1	Q. Would it be fair to say that when it comes to the
	2	precaution section, the three places we've marked, which is
	3	here at the beginning (indicating), here in akathisia
	4	(indicating), and here in the clinical worsening and suicide
10:48:12	5	section, those are the places in the precautions that it made
	6	the more sense to a Paxil-specific warning?
	7	A. Yes.
	8	Q. Okay. Let's keep going through this. Let's get to the end
	9	of the precaution section because there's a bunch of oh,
10:48:23	10	sorry, I skipped a section.
	11	(Brief pause).
	12	BY MR. WISNER:
	13	Q. All right. So all these are referring to using it with
	14	another drug, is that right?
10:48:40	15	A. Yes.
	16	Q. Okay. So I'll skip through all this.
	17	All right, now we're in the next section. There we
	18	go.
	19	What is this section, Doctor.
10:48:54	20	A. So this section lists side effects, both those that were
	21	observed in terms of the original trials and then later on
	22	adverse events that have been observed either in postmarketing
	23	trials conducted after approved or just from side effect
	24	reports that get submitted to the FDA.
10:49:17	25	Q. And adverse reaction, is suicide attempt an adverse

		Ross - direct by Wisner 1174
	1	reaction?
	2	A. Yes.
	3	Q. A suicide is an adverse reaction?
	4	A. Yes.
10:49:30	5	Q. Would you characterize it how would you characterize it
	6	in the spectrum of adverse reactions?
	7	A. Those are serious adverse events.
	8	Q. All right. So right here at the beginning of adverse
	9	reaction, you see "associated with discontinuation of
10:49:40	10	treatment"?
	11	A. Yes.
	12	Q. That word "associated," does that have any special meaning
	13	in the context of regulatory speak?
	14	A. So basically "associated" means it happens more often in
10:49:57	15	people who get the drug than people who don't.
	16	Q. All right. And do you have to have a statistically
	17	significant increase to say you have an association?
	18	A. No.
	19	Q. What do you need?
10:50:09	20	A. You need reasonable evidence of an association.
	21	Q. And when you look for that reasonable evidence, do you
	22	exclude adverse reactions that happen in clinical trials that
	23	weren't placebo controlled?
	24	A. No.
10:50:23	25	Q. Why not?

1175

	1	A. You actually let me go back for a second. I want to
	2	clarify something. When I say it happens more often in people
	3	who take the drug than those who don't, that's one factor. If
	4	it's something where you don't have enough numbers to show that
10:50:52	5	that happens but the circumstances are so overwhelming you know
	6	that the drug had something to do with it, like you gave the
	7	person the drug and they dropped dead a minute later, that's
	8	sort of the thing. You know, it's out of one, as we say it's
	9	one person, but that's extremely compelling evidence. And
10:51:19	10	sometimes that has been used on the basis of case reports that
	11	are compelling submitted to the FDA and I personally would
	12	approve those kind of supplements.
	13	Q. What about other types of analysis like challenge,
	14	de-challenge, re-challenge?
10:51:37	15	A. Yes, exactly. If something happens when you take the drug
	16	and then when you take the drug it goes away, that's called a
	17	de-challenge. A challenge is when you give it and something
	18	happens and you take it away is called a de-challenge, and if
	19	the side effect goes away, that's pretty good evidence it has
10:51:57	20	something to do with it.
	21	Q. And then what about re-challenge?
	22	A. Re-challenge, if it happens again I'm sorry, I've got to
	23	use this line: There's there's a James Bond novel where
	24	Fleming wrote the first time it happens, it's coincidence, the
10:52:13	25	second time is happenstance, the third time it's enemy action.

		Ross - direct by Wisner 1176
	1	So that's really
	2	MR. BAYMAN: Your Honor, I object to that. Move to
	3	strike that.
	4	THE COURT: Yeah, that may go out.
10:52:24	5	BY MR. WISNER:
	6	Q. All right. So adverse reactions, do you have an opinion
	7	about whether or not GSK could have or should have put the
	8	adverse reaction of suicide attempt or suicides in this
	9	section?
10:52:41	10	A. Yes.
	11	Q. Where could they put it?
	12	A. There's a number of places. So what the adverse reaction
	13	section is, and it's not just something that's mutually
	14	exclusive with warnings, this gives actual frequencies.
10:52:56	15	Q. So where could they have gone?
	16	A. So if we could go to the next page.
	17	Q. Sure.
	18	Doctor, before we go on to the next page, I just want
	19	to ask you a quick question before we go there.
10:53:06	20	A. Yes.
	21	Q. There's a section here that says associated with
	22	discontinuation of treatment, do you see that?
	23	A. Yes.
	24	Q. Could you have created a section right here (indicating)?
10:53:16	25	A. Oh, yeah. I'm sorry. Yes, you absolutely could do that.


		Ross - direct by Wisner 1177
	1	There's no question about it.
	2	Q. Okay.
	3	A. Again, if you want to make it more prominent calling it out
	4	at the beginning and having a separate section is something you
10:53:31	5	can absolutely do.
	6	Q. All right. Well, let's go through here. And you said
	7	there's like a table here for discontinuation and there's a
	8	bunch of percentages and stuff, do you see that?
	9	A. Yes.
10:53:37	10	Q. Showing, you know, what shows like, you know, dizziness, do
	11	you see that?
	12	A. Yes.
	13	Q. Let's go to tremor, do you see that?
	14	A. Yes.
10:53:47	15	Q. And it has 1.1 percent right here (indicating)?
	16	A. Yes.
	17	Q. And then .03 percent, do you see that?
	18	A. Yes.
	19	Q. So what does that tell us based on and it's also under
10:54:01	20	major depressive disorder, do you see that?
	21	A. Yes.
	22	Q. So what does that tell us about agitation for people taking
	23	Paxil?
	24	A. It's more than two times greater in patients with MDD than
10:54:12	25	a placebo.


		Ross - direct by Wisner 1178
	1	Q. And you're making that calculation because they're
	2	comparing .03 percent to 1.1, is that right?
	3	A. No, I'm sorry, 0.5 percent with 1.1 percent.
	4	Q. Oh, you're talking about agitation?
10:54:27	5	A. Yes.
	6	Q. Okay. So there's a doubling of the incidents of agitation
	7	for people who are depressed who take Paxil versus people who
	8	take a sugar pill?
	9	A. Yes.
10:54:37	10	Q. Okay. Tremor, what was the increase there?
	11	A. Almost 4 times.
	12	Q. Okay. Great. And then you see all these numbers for all
	13	these different indications, do you see that?
	14	A. Yes.
10:54:43	15	Q. Including, for example, like PTSD?
	16	A. Yes.
	17	Q. And I know you have some experience with PTSD because you
	18	treat veterans. Do you see this number here 1.2?
	19	A. Yes.
10:54:57	20	Q. What does that tell you about tremor?
	21	A. Well, if you have a PTSD patient and this was I'm sorry,
	22	I gotta mention this just in terms of interpreting this data,
	23	this was not a real world PTSD patient population
	24	MR. BAYMAN: Your Honor, I object to this. We're now
10:55:13	25	getting into PTSD patient populations and discontinuation, ${f I}$


		Ross - direct by Wisner 1179
	1	don't see what this has to do with this case. It's entirely
	2	irrelevant and prejudicial.
	3	THE COURT: All right.
	4	MR. WISNER: Your Honor, we're just trying to
10:55:27	5	understand how the label is read.
	6	THE COURT: To the extent that you raised the point
	7	that it is not part of the case, I'll sustain the objection.
	8	To the extent that you're trying to explain how this fits in
	9	the chart, he may answer that question; in other words, why is
10:55:43	10	PTSD over here rather than somewhere else.
	11	BY MR. WISNER:
	12	Q. So, Doctor, I don't want to hear about the population.
	13	A. Understood. I apologize.
	14	So these are the indications in which Paxil has been
10:55:56	15	studied, and PTSD is one of them, so the incidents of tremor in
	16	patients with PTSD who got Paxil is 5 times than in patients
	17	who just got a placebo.
	18	Q. All right. If you go down to some more of these adverse
	19	reactions you see "commonly observed adverse events, major
10:56:19	20	depressive disorder," do you see that?
	21	A. Yes.
	22	Q. So this is where you could list common events that you
	23	would expect to see with people who are depressed?
	24	A. Yes.
10:56:27	25	Q. Okay. And it has different things in here. It has


		Ross - direct by Wisner 1180
	1	asthenia, that's not akathisia, right?
	2	A. Correct.
	3	Q. And you have a bunch of different here, sweating, nausea
	4	decreased appetite, et cetera, do you see that?
10:56:46	5	A. Yes.
	6	Q. And those are all just adverse reactions?
	7	A. Yes.
	8	Q. Okay. So this is for the area of associated with
	9	discontinuation, is that right?
10:56:52	10	A. Yes.
	11	Q. Okay. Let's move on.
	12	I just want to take a second to discuss this. So just
	13	for discontinuation there's a chart, there's a section, do you
	14	see that?
10:57:04	15	A. Yes.
	16	Q. All right. And it keeps going, do you see all that?
	17	A. Yes.
	18	Q. And then we get to a new one here which is incidents of
	19	controlled clinical trials, do you see that?
10:57:16	20	A. Yes.
	21	Q. So there's already almost a page and a half, two pages,
	22	just devoted to discontinuation symptoms?
	23	A. Can you I just want to make sure I'm understanding it
	24	correctly. Can we go back.
10:57:31	25	Q. That's the first part (indicating).

		Ross - direct by Wisner 1181
	1	A. Right.
	2	Q. By the way, you have a copy of it in your binder.
	3	A. I'm sorry, which?
	4	Q. Joint Exhibit 1.
10:57:38	5	A. Joint Exhibit 1.
	6	Q. That actually might be helpful in case you want to look at
	7	something I'm not showing you.
	8	We're on page 25, Doctor.
	9	THE COURT: We'll take a recess at this time, ladies
10:58:06	10	and gentlemen.
	11	Mike, open the door for them.
	12	(The following proceedings were had out of the
	13	presence of the jury in open court:)
	14	
10:58:32	15	
	16	
	17	
	18	
	19	
10:58:50	20	
	21	
	22	
	23	
	24	
10:59:11	25	









		Ross - direct by Wisner 1186
	1	(Brief pause).
	2	BY MR. WISNER:
	3	Q. Okay, Doctor, you have the water there.
	4	A. Thank you.
11:22:06	5	Q. All right. So before the break we were talking about
	6	adverse reactions and relating to this section right here, do
	7	you see that?
	8	A. Yes.
	9	Q. Okay. And just for the record, we're on page 25 of Joint
11:22:26	10	Exhibit 1.
	11	A. Yes.
	12	Q. This states:
	13	" adverse reactions associated with
	14	discontinuation of treatment."
11:22:33	15	Do you see that?
	16	A. Yes.
	17	Q. Is this section referring to the reasons why in clinical
	18	trials patients stopped participating in the trials?
	19	A. Yes.
11:22:46	20	Q. Okay. So that's a little different than, for example, the
	21	symptoms that somebody has when they stopped taking the drug,
	22	in general?
	23	A. Well, these these refer to is this working
	24	(indicating to the microphone).
11:23:03	25	These refer to symptoms that are sufficiently severe

		Ross - direct by Wisner
		1187
	1	that they lead to either the patient or the investigator at the
	2	site saying let's take you out of the trial.
	3	Q. So, for example, it says right here "discontinue treatment
	4	due to a adverse event," that's what you're referring to?
11:23:23	5	A. Yes.
	6	Q. So these were so severe that in the clinical trial itself
	7	patients were actually removed from the trial?
	8	A. Yes.
	9	Q. Okay. And then we go to this chart, it talks about, for
11:23:36	10	example, major depressive disorder, do you see that?
	11	A. Yes.
	12	Q. And that's referring to clinical trials related to major
	13	depress disorder, right?
	14	A. Yes.
11:23:46	15	Q. And while on that point, I just want to make sure we have
	16	an understanding, is there a difference between what we see in
	17	people who have commonly known depression and major depressive
	18	disorder?
	19	A. Well, the definition of major depressive disorder
11:24:02	20	everyone feels down once in a while. A major depressive
	21	disorder is a specific diagnosis in which
	22	Is this working (indicating microphone)?
	23	Q. Yes, it is.
	24	A. A patient has 5 out of 9 specific symptoms for majority for
11:24:26	25	at least 2 weeks.

		Ross - direct by Wisner 1188
	1	Q. And for and our understanding of depression, as we
	2	understand it today in common parlance, is that different than
	3	the type of depression that we were talking about in the
	4	1950's, line melancholia?
11:24:45	5	A. Yes.
	6	Q. And has the general definition for depression expanded in
	7	people that we considered depressed over the years?
	8	MR. BAYMAN: Objection, Your Honor. No foundation for
	9	this testimony from this witness. He's not a psychiatrist. He
11:24:56	10	is an internist with a specialty in infectious disease.
	11	THE COURT: Overruled.
	12	BY THE WITNESS:
	13	A. Thank you.
	14	So in terms of the first let me clarify. The
11:25:11	15	mechanism I'm sorry. Depression as a primary care disorder,
	16	I am revising an edition of a book on primary for veterans with
	17	HIV, one of the major chapters is depression with the
	18	implication that this is something that the primary care
	19	providers should be responsible for.
11:25:35	20	Having said that, the criteria for diagnosing it have
	21	been refined and improved considerably over the last several
	22	decades. So that it's no longer when you're feeling down once
	23	in a while, that's too broad, too vague. On the other hand,
	24	there's an appreciation that certain symptoms that previously
11:25:59	25	had not been thought of as depressionfor example, insomnia or

		Ross - direct by Wisner 1189
	1	hypersomnolencemay actually represent signs of depression.
	2	Q. Sorry, Doctor, hypersomnolence?
	2	A. Sleeping a lot.
	4	Q. Okay. All right. So we're looking here at a table and we
44.00.00	5	have major depressive disorder, and these are all side effects
11:26:22	6	that cause people to leave the study, is that right?
	7	A. Correct.
	8	
	9	Q. Okay. So with that in mind, 1 percent of all patients in depression trials who took Paxil quit the trial because the
	9 10	tremors were so bad?
11:26:46	11	A. Yes.
	12	Q. 1 percent of patients who took Paxil had such bad agitation
	13	that they left the trial?
	14	MR. BAYMAN: Leading, Your Honor.
11:26:59	15	BY THE WITNESS:
	16	A. Correct.
	17	BY MR. WISNER:
	18	Q. What does that 1.1 percent mean with agitation, Doctor?
	19	THE COURT: Excuse me. Did you say something?
11:27:09	20	MR. BAYMAN: Objection. Leading, Your Honor.
	21	THE COURT: Oh, leading, yes. Don't lead. Just ask
	22	the questions.
	23	MR. WISNER: I'll rephrase. I'm sorry. That is open
	24	ended question.
11:27:16	25	BY MR. WISNER:

		Ross - direct by Wisner 1190
	1	Q. What does that 1.1 percent agitation mean?
	2	A. So of the hang on here.
	3	If I can just go up to the introductory paragraph.
	4	Q. So own page 25 here.
11:27:28	5	A. Yes.
	6	(Brief pause).
	7	BY THE WITNESS:
	8	A. So if you look at the first sentence, 20 percent, one out
	9	of every 5 patients who received trials I'm sorry, Paxil in
11:27:48	10	clinical trials in major depressive disorder, and that's about
	11	1200 patients, stopped the drug because of a side effect.
	12	That's where it says at the end, "discontinued treatment due to
	13	a suicidal event."
	14	Q. Okay.
11:28:09	15	A. And sometimes patients can stop for more than one.
	16	Q. All right. And then we have a bunch of other types of
	17	things in here, do you see that?
	18	A. Yes.
	19	Q. So, for example, like nausea. So what does that 3.2
11:28:19	20	percent mean?
	21	A. Those patients, or 0 those 1200 patients who stopped, 3.2
	22	percent discontinued because of nausea as opposed to only 1
	23	percent in placebo patients who stopped treatment.
	24	Q. And so for when we go back up here like tremor, the 1.1
11:28:39	25	percent, how many percent greater is that than placebo?

		Ross - direct by Wisner 1191
	1	A. That's almost 4 times greater.
	2	Q. So in all MDD clinical trials, what does that tell you
	3	about the people quitting the trial because of tremor?
	4	A. Well, it's I don't want to say statistically significantly
11:29:04	5	greater, I haven't done that analysis on this, but it's a lot
	6	more.
	7	Q. All right.
	8	A. May I if I may just offer one observation which I
	9	believe is important in terms of understanding this table.
11:29:18	10	So if
	11	MR. BAYMAN: Objection, Your Honor. I don't see what
	12	this has to do with any of the issues in this case.
	13	THE COURT: We'll see.
	14	BY THE WITNESS:
11:29:28	15	A. I mentioned earlier that depression requires a diagnosis
	16	according to current criteria 5 out of 9 symptoms over a period
	17	of 2 weeks. If you break up those 5 symptoms in just if
	18	somebody has 5 of those symptoms that you count them
	19	independently and you don't consider them together, then you
11:29:51	20	will conclude that the reason for discontinuation is that
	21	particular symptom rather than depression.
	22	So, for example, the first line is somnolence,
	23	sleeping a lot. The question here is, if you say, well, it
	24	turns out that patient also had anxiety and insomnia, and what
11:30:24	25	can be mixed with somnolence and so on and they really had

		Ross - direct by Wisner 1192
	1	depression, you are going to shift what the reason for
	2	adverse events should be depression discontinuation, rather,
	3	should be depression, but here it gets to capture somnolence.
	4	So it's a question of how it's covered.
11:30:46	5	Q. All right. That said, in a clinical trial if a patient on
	6	Paxil or placebo attempts suicide, are they typically removed
	7	from the clinical trial?
	8	A. Typically, yes.
	9	Q. So suicide attempt would be a reason for discontinuing from
11:31:04	10	a clinical trial?
	11	A. Yes.
	12	Q. Do you see anywhere here any statement about suicide
	13	attempts or the likelihood of it occurring in these various
	14	indications?
11:31:13	15	A. No.
	16	Q. We know, Doctor, from the 1989 data, what was the risk
	17	ratio between suicide attempts in Paxil and suicide attempts in
	18	placebo?
	19	A. I believe it was roughly a non-fold difference, if I'm
11:31:31	20	remembering correctly.
	21	Q. So that if it were to be written in here, it would say
	22	suicide attempt and then 9 percent, is that right?
	23	A. Well, no, not 9 percent, but the
	24	Q. Well, the incidents
11:31:46	25	A. The incident events would be greater. The odd it might

1193

	1	not be 9 percent, but it certainly would be listed in this
	2	table with the incidents. This table does not give odds ratio,
	3	but you can calculate them like we just did with tremor where
	4	the odds ratio there is almost 4.
11:32:09	5	Q. Now, we also looked at a re-analysis done by GSK in 2002
	6	just looking at placebo-controlled date, do you recall that?
	7	A. Yes.
	8	${\tt Q}$. And we just put the placebo number aside for just one
	9	second and we looked at just suicide attempt and the incident
11:32:25	10	rate, do you remember that?
	11	A. Yes.
	12	Q. And do you recall it was about 1.2 percent?
	13	A. Yes.
	14	Q. So 1.2 just the placebo controlled data of people who
11:32:37	15	attempted or committed suicide in the MDD trials, is that
	16	right?
	17	A. Yes.
	18	Q. And 1 percent of those incident rates for suicide attempts,
	19	in your opinion, should that information have been put right
11:32:49	20	here in this table as a reason for discontinuing the study?
	21	A. Yes.
	22	Q. All right. Doctor, let's move on. We're in the process of
	23	exploring places where they could've put warnings. Are we in
	24	one of those areas now?
11:33:09	25	A. Yes.

		Ross - direct by Wisner 1194
	1	Q. Where would you have put it?
	2	A. So now keeping in mind that this section generally provides
	3	numbers
	4	Q. Hold on. Before we get to that.
11:33:34	5	A. I'm sorry.
	6	Q. On this table right here, could they put something?
	7	A. Oh, yeah. In fact, if you look at there's a couple of
	8	different ways. They could put you know, on suicide attempt
	9	would not necessarily go under CNS, but it could, but certainly
11:33:57	10	it should be in there.
	11	Q. So you said it could've have been CNS, what about under
	12	other, could it have gone there too?
	13	A. Yes. Although, again, I think that's sufficiently
	14	important that you'd want to put it someplace prominent.
11:34:12	15	Q. All right. So should I put an arrow under CNS and other
	16	there?
	17	A. Yes.
	18	Q. All right.
	19	THE COURT: Again, what does CNS mean?
11:34:33	20	THE WITNESS: Central nervous system, Your Honor.
	21	THE COURT: Ah, central nervous system.
	22	BY MR. WISNER:
	23	Q. What number are we at here, doctor, do you know?
	24	THE COURT: But you're saying that it could have been
11:34:36	25	more data could have included, is that what you're saying?

		Ross – direct by Wisner 1195
	1	Or should've been?
	2	THE WITNESS: Yes, the latter, Your Honor.
	3	THE COURT: But we don't know what the drop-out rate
	4	was well, we know what the base was, the base was the 20
11:34:56	5	percent shown at the top, right?
	6	THE WITNESS: Yes, sir.
	7	THE COURT: Okay.
	8	BY THE WITNESS:
	9	A. If I may just add one comment?
11:35:03	10	There are a number of areas on this table where
	11	there's dashes. And so if there's not sufficient numbers or
	12	you can't calculate an exact rate but you know that it is
	13	something where it's greater in Paxil than placebo, it could
	14	also be put in in that form.
11:35:23	15	BY MR. WISNER:
	16	Q. Sure. But we know as of 1989, before the drug ever came on
	17	the market, there was 1.2 percent increase?
	18	A. Correct. But certainly if those patients are discontinued,
	19	that enumerator would be 47, assuming all 47 of them were
11:35:46	20	discontinued because of the suicide attempt.
	21	Q. So I'll number this as 11, Doctor.
	22	THE COURT: I'm sorry, what enumerator are you
	23	referring to? On page 25?
	24	THE WITNESS: No, Your Honor. This was an analysis
11:35:59	25	that

		Ross - direct by Wisner 1196
	1	THE COURT: But the enumerator is not on page 25, is
	2	it, that you're referring to?
	-	THE WITNESS: No, sir.
	4	THE COURT: Okay.
11:36:08	5	BY MR. WISNER:
	6	Q. Just to be clear, Doctor, the enumerator would be suicide
	7	attempts, right?
	8	A. Correct.
	9	Q. And there's no statement of the number of suicide attempts
11:36:15	10	here at all?
	11	A. That's exactly.
	12	Q. All right. Let's keep going.
	13	So, Doctor, let's look at that next section and it
	14	actually starts at the bottom of that page that we were just
11:36:36	15	on. It says "Commonly Observed Suicidal Events, Major
	16	Depressive Disorder," do you see that?
	17	A. Yes.
	18	Q. So in this section of commonly observed adverse events,
	19	what's supposed to go in there?
11:36:47	20	A. So these are events that occur in 5 percent of more
	21	patients receiving Paxil and where the incidents is at least
	22	twice that as what is observed in a placebo.
	23	Q. All right. Now, we know, Doctor, from the FDA study that
	24	there's a doubling of the risk with Paxil, is that right, over
11:37:07	25	placebo?

		Ross - direct by Wisner 1197
	1	A. Yes.
	2	Q. But that 2.76, that's not high enough incident rate to meet
	3	that 5 percent threshold, is that right?
	4	A. Correct.
11:37:17	5	Q. All right. So this next section goes breaks it down by
	6	different conditions, do you see that, Doctor?
	7	A. Yes.
	8	Q. Okay. Let's move on to the next section, Incidents of
	9	Controlled Clinical Trials, what does that refer to?
11:37:37	10	A. So this refers to how frequently or less, actually,
	11	suicidal events that were observed in uncontrolled clinical
	12	trials not it excludes trials where that were uncontrolled,
	13	basically.
	14	Q. All right. And you have one here for major depressive
11:38:08	15	disorder, do you see that?
	16	A. Yes.
	17	Q. And it says, table 2 enumerates adverse events that
	18	occurred of an incident of 1 percent or more?
	19	A. Yes.
11:38:19	20	Q. So let's look at the table, all right. Can I turn the
	21	page?
	22	A. Yes.
	23	Q. All right. So now we're looking at "treatment emergent
	24	adverse experience," do you see that?
11:38:26	25	A. Yes.

		Ross - direct by Wisner 1198
	1	Q. What does that mean in basic English?
	2	A. Side effects that happen while you're getting the drug or
	3	after you've started the drug.
	4	Q. So, for example, there was an incident that happened, you
11:38:41	5	know, in the washout period before you started, would that
	6	qualified as a treatment emergent adverse experience?
	7	A. No.
	8	Q. Okay. All right. And so we have here a bunch of different
	9	adverse effects, do you see that, Doctor?
11:38:57	10	A. Yes.
	11	Q. And we have the percentage of people who are experiencing
	12	it on Paxil versus placebo, do you see that?
	13	A. Yes.
	14	${\tt Q}$. And these percentages here reflect the results from MDD
11:39:10	15	trials, is that right?
	16	A. Correct. Placebo-controlled MDD trials.
	17	Q. Thank you, Doctor.
	18	And so we have here "nervous system" and we have all
	19	these different things that would be classified under nervous
11:39:23	20	system, do you see that?
	21	A. Yes.
	22	Q. Now if there was and it all starts at 1 percent and
	23	moves up to 23 percent, right?
	24	A. Correct.
11:39:30	25	Q. And so let's take a quick look at tremor, 8 percent.

		Ross - direct by Wisner 1199
	1	A. Yes.
	2	Q. What does that mean relative to the 2 percent on placebo?
	3	A. So tremor happened 4 times more often in patients exposed
	4	to Paxil than in those who received placebo.
11:39:46	5	Q. I mean this might sound obvious to some, but what is
	6	"tremor"?
	7	A. It's where you're shaking.
	8	Q. Okay. We also see nervousness here, do you see that?
	9	A. Yes.
11:40:02	10	Q. And again, is that an elevated incident rate with Paxil?
	11	A. Yes. And, again, just to clarify, these are treatment
	12	emergent. They weren't there from the get go.
	13	Q. This is after they started taking the drug?
	14	A. Correct.
11:40:17	15	Q. Okay. "Drugged feeling," what's that?
	16	A. You feel out of it.
	17	Q. And again, we also have zero percent on confusion and 1
	18	percent for Paxil, do you see that?
	19	A. Yes.
11:40:29	20	Q. Okay. And again, this is an elevated incident rate of
	21	Paxil versus placebo, is that right?
	22	A. Yes.
	23	Q. Now, I see this goes down to descending order.
	24	Is suicide attempt in there?
11:40:47	25	A. No.

		Ross - direct by Wisner 1200
	1	Q. And do we know that it should be?
	2	A. So it should be. The incidents in MDD studies altogether
	3	was greater than in placebo.
	4	Q. And you know that from the data from 1989?
11:41:07	5	A. Yes.
	6	Q. Okay. So where would we put it in here? I guess it's 1
	7	percent, so is it above or below "confusion"?
	8	A. It would be above.
	9	Q. Okay. All right. So another area they could've put
11:41:25	10	something, right?
	11	A. Yes.
	12	Q. Okay. And then it goes on. And I don't want to spend too
	13	much time because we'll be here all day. This is a fairly
	14	lengthy label. But you have the same charts for obsessive
11:41:38	15	compulsive disorder, panic disorder, social anxiety disorder,
	16	do you see that?
	17	A. Yes.
	18	Q. And then it has another chart there with all the different
	19	frequencies, and that's on page 30. Then there's a whole
11:41:49	20	section that specifically relates to generalized anxiety
	21	disorder, do you see that?
	22	A. Yes.
	23	Q. And again, if we turn that's page 31, if we turn the
	24	page to page 32 we have the chart here, is that right?
11:42:07	25	A. Yes.

		Ross - direct by Wisner 1201
	1	
	1	Q. And the way we read the chart for depression, you could
	2	read the chart here the same way?
	3	A. Yes.
	4	Q. All right. So we're not going to go through all those
11:42:17	5	again.
	6	Down here it says "dose dependency of adverse events,"
	7	what does that refer to, Doctor?
	8	A. So if a drug causes an adverse event, the more the drug you
	9	give, the more frequent the side effect, more often it should
11:42:40	10	happen.
	11	So if you compare what happens on different doses,
	12	it's useful in saying is this a side effect that is associated
	13	with use of the drug.
	14	MR. BAYMAN: Your Honor, once again, Dr. Ross has
11:43:00	15	given no opinions on dosage and I would like a continuing
	16	objection to this line of questioning, to the extent I haven'
	17	already.
	18	THE COURT: Yes, so noted.
	19	MR. BAYMAN: Thank you.
11:43:10	20	BY MR. WISNER:
	21	Q. All right. So let's turn to the table that comes with dose
	22	dependence.
	23	Do you see that, Doctor?
	24	A. Yes.
11:43:19	25	Q. And that's table 5 in the adverse event section, is that

		Ross - direct by Wisner 1202
	1	right?
	2	A. Yes.
	3	Q. All right. This is page 33.
	4	So we have here, on the top, we have the placebo,
11:43:32	5	right?
	6	A. Yes.
	7	Q. And can you have different doses of placebo? Is that
	8	possible?
	9	A. Ah, no.
11:43:45	10	Q. Okay.
	11	A. It's a fair question, but no.
	12	Q. Okay. And then you have 10 milligram, 20 milligram, 30
	13	milligram, 40 milligram, do you see that?
	14	A. Yes.
11:43:57	15	Q. Okay. And this shows the various symptoms that occur based
	16	on increase the dose, is that right?
	17	A. Yes.
	18	Q. So again look at this nervous system. I just want to point
	19	out a few just so that we can get a sense of it.
11:44:15	20	Let's look at "nervousness," right here (indicating).
	21	Do you see "nervousness"?
	22	A. Yes.
	23	Q. At dose is the incidents of nervousness the highest for
	24	Paxil?
11:44:26	25	A. According to this table, 10 milligrams.

		Ross - direct by Wisner 1203
	1	Q. So, in fact, the lowest designated dose actually causes the
	2	most amount of nervousness, do you see that?
	3	A. Yes.
	4	Q. Okay. And we see this we see different percentages, but
11:44:42	5	we also see a significant amount for other things like anxiety,
	6	do you see that? 2 percent experienced anxiety?
	7	A. Yes.
	8	Q. And we don't see any we see paresthesia, what is that,
	9	do you know, Doctor?
11:44:57	10	A. It's when your foot feels like it's falling asleep. You
	11	get tingling or numbness usually in the feet.
	12	Q. Okay. Are you aware of whether or not it also applies to
	13	the psychological phenomena in your head? I'm just curious if
	14	you know anything about that.
11:45:13	15	A. It certainly can be exacerbated by that.
	16	Q. Okay. All right, this is a section I mean, Doctor, have
	17	you seen any data about the dose relationship in suicidal
	18	attempts or is that something you haven't seen?
	19	A. No, but I just want to call attention to the line sorry,
11:45:36	20	this is "marked somnolence," and this is a really good
	21	illustration of what we refer to as a dose-response effect.
	22	So the placebo rate of somnolence, and again this
	23	sleeping a lot, or feeling like you want to get in bed and pull
	24	the covers over your head, placebo at 7.8 percent, at 10
11:46:03	25	milligrams 12.7 percent, it increases to 18.3 percent if you go

		Ross - direct by Wisner
		1204
	1	to 20 milligrams, 30 milligrams it goes up to 20.8 percent, and
	2	then at the highest dose tested at 21.6 percent.
	3	I mean, you don't necessarily expect as you double the
	4	dose, the incidents of something is going to go up in the same
11:46:26	5	proportion, but this is a clear dose-response trend.
	6	Q. Okay. Thank you for explaining that, Doctor.
	7	All right. Let's clear this out.
	8	(Brief pause).
	9	BY MR. WISNER:
11:46:43	10	Q. It goes on to explain other types of stuff like adaption of
	11	adverse events, to certain adverse events. What does
	12	adaptation of adverse events mean?
	13	A. You get used to it.
	14	Q. Have you heard the word habituation?
11:47:04	15	A. Yes.
	16	Q. What does that mean? Is that the same thing?
	17	A. It's close in meaning.
	18	Q. Well, what does it mean
	19	MR. BAYMAN: Objection, Your Honor. I think we're now
11:47:09	20	getting into causation opinions here, going into habituation.
	21	So I would object to this line of questioning also. It's not
	22	in his report or in his depression.
	23	MR. WISNER: I'm asking what it means.
	24	THE COURT: Habituation?
11:47:21	25	MR. WISNER: Habituation, yes.

		Ross - direct by Wisner 1205
	1	THE COURT: Do we need it?
	2	MR. WISNER: Well, we heard Dr. Healy talk about it.
	3	I just wanted to see if it's the same thing.
	4	MR. BAYMAN: He talked about causation, Your Honor,
11:47:31	5	that's what Dr. Healy talked about. I object to this line of
	6	questioning.
	7	MR. WISNER: Well, I asked about causation. He's the
	8	one that objected to it.
	9	THE COURT: All right. Go on to something else.
11:47:42	10	MR. WISNER: Okay.
	11	BY MR. WISNER:
	12	Q. All right. It says here over 4 to 6 week period there was
	13	evidence of adaptation to some adverse events with continued
	14	therapy, do you see that?
11:47:51	15	A. Yes.
	16	Q. And lists an example, nausea and dizziness, do yo usee
	17	that?
	18	A. Yes.
	19	Q. Okay. Is there any reference here to akathisia?
11:48:00	20	A. No.
	21	Q. It says "asthenia," do you see that?
	22	A. Yes.
	23	Q. Is that akathisia?
	24	A. No.
11:48:07	25	Q. Okay. What is asthenia, just so we're not falling asleep

		Ross - direct by Wisner 1206
	1	on this.
	2	A. Kind of like feeling weak, feeling tired out. It's
	3	actually a specific term in the coding dictionary.
	4	Q. Okay. Then it goes into differences with males and
11:48:25	5	females, Doctor, do you see that?
	6	A. Yes.
	7	Q. All right. Let's go down here, it has discussions, it has
	8	hallucinations, do you see that?
	9	A. Yes.
11:48:35	10	Q. All right. So now let's get to the next section. What is
	11	that section, Doctor?
	12	A. So anything that wasn't captured above, basically, that did
	13	not was was was not didn't meet the definition of
	14	common, or discontinuation, or frequent. Basically, this is
11:49:06	15	almost like a miscellaneous listing of things.
	16	Q. Is this where you look to if you missed anything earlier?
	17	A. If yes.
	18	Q. All right. And yesterday we went through the 1992 label
	19	for Paxil, do you recall that?
11:49:25	20	A. Yes.
	21	Q. Is this the same section where we saw the "emotion
	22	lability" term?
	23	A. Yes.
	24	Q. And that was back in 1992, right?
11:49:34	25	A. Correct.

		Ross - direct by Wisner 1207
	1	Q. So this is 2010. How many years later is this?
	2	A. 18.
	3	Q. Okay. All right. And we have the same text, essentially,
	4	that we saw in the '92 label, is that right, Doctor?
11:49:47	5	A. Yes, with the exception that, you know, there may have been
	6	some things added and this would be through CBE, change being
	7	affected in supplements.
	8	Q. Okay. And, for example, the number of patients has
	9	obviously increased?
11:50:02	10	A. Yes.
	11	Q. Okay. Now, the bottom here it says:
	12	"The events are further categorized by body
	13	system and listed in order of decreasing
	14	frequency according to the definitions."
11:50:14	15	Do you see that?
	16	A. Yes.
	17	Q. And is that the same definition of "frequent" that you
	18	discussed with the jury yesterday?
	19	A. Yes.
11:50:19	20	Q. And so it's still in the label today?
	21	A. Correct.
	22	Q. All right. Let's turn the page.
	23	Remember yesterday we discussed the nervous system?
	24	A. Yes.
11:50:32	25	Q. And the listing of frequents adverse events?
		1

		Ross - direct by Wisner 1208
	1	A. Yes.
	2	Q. Do you see a frequent adverse event in there of suicide
	3	attempt?
	4	A. No.
11:50:44	5	Q. What do you see?
	6	A. Emotional lability.
	7	Q. That's the term we looked at yesterday where the FDA was
	8	talking about coding maneuvers, is that right?
	9	A. Correct.
11:50:58	10	Q. Doctor, in your opinion, is that use of emotional lability
	11	misleading?
	12	A. Yes.
	13	Q. Why?
	14	A. It should have been coded. These events were actually
11:51:16	15	suicide attempts, that's number one. From a regulatory point
	16	of view so if you saw "suicide attempt" there, that means
	17	it's something very different than emotional lability.
	18	Number two, and this is a regulatory issue, it says "a
	19	standard COSTART based dictionary terminology." Suicide
11:51:33	20	attempt so the specific terms, not these are technical
	21	terms, even though they may have a common meaning, COSTARTand
	22	that dictionary is no longer in usebut suicide attempt is the
	23	appropriate COSTART term.
	24	Q. So emotional lability, it wasn't that they had to use it,
11:51:55	25	they could've used "suicide attempt"?

		Ross - direct by Wisner 1209
	1	A. I'm not even sure
	2	MR. BAYMAN: Objection; leading, Your Honor.
	3	THE COURT: He may answer.
	4	BY THE WITNESS:
11:52:02	5	A. I'm not even sure that emotional lability is a term in
	6	COSTART. I mean, it might be, but it's it's it's
	7	something that it's not the right word. It's just not.
	8	Q. Since we're on this point, Doctor, I've pulled up the red
	9	pen. Is this a good time to use it?
11:52:22	10	A. Certainly.
	11	Q. All right. What should I circle or underline?
	12	A. I would circle "emotional lability."
	13	Q. And what do you have to say about that, Doctor?
	14	A. Well, it's not only the wrong term, but it's buried. I
11:52:44	15	mean, the average prescriber is not going I don't go through
	16	these list unless I've got some patient with an extraordinary
	17	unexpected event, and I say has this ever been reported
	18	anywhere.
	19	So it's it's you can say, well we said there's
11:53:05	20	emotional lability, you'd have to know what that meant and then
	21	you'd have to go through this whole label. It's not an
	22	effective warning.
	23	Q. So it would be fair to say suicide, suicide hidden?
	24	A. Suicide not even mentioned.
11:53:19	25	Q. So no suicide?

		Ross - direct by Wisner 1210
	1	A. Correct. Or suicide attempt. Again, those are two
	2	different concepts, or suicidal behavior.
	3	Q. My handwriting is terrible, but did I write "no suicide, or
	4	suicide attempt, or suicidal behavior"?
11:53:49	5	A. Correct.
	6	Q. Okay. And just to be clear, Doctor, I mean, this is the
	7	current label, is this the same thing that's happened since
	8	1992?
	9	A. Yes, this is well, again, just to be clear, this is the
11:54:04	10	2010 label.
	11	Q. I'm sorry, Doctor. This is a 2010 label. Is this the same
	12	thing that's happened since 1992?
	13	A. Yes.
	14	Q. And in your opinion, as a regulatory expert, did GSK have
11:54:17	15	an obligation to fix this term right here (indicating) with
	16	"suicide attempt"?
	17	A. Yes.
	18	Q. And after the FDA investigated this issue with regards to
	19	the pediatrics, did that add a heightened obligation on GSK to
11:54:36	20	change the label?
	21	MR. BAYMAN: Objection, Your Honor.
	22	THE COURT: Overruled.
	23	BY THE WITNESS:
	24	A. Yes.
11:54:39	25	BY MR. WISNER:

		Ross - direct by Wisner 1211
	1	Q. Did they ever try?
	2	A. I'm not aware of any attempt.
	3	I want to clarify one thing, though, because we did
	4	agree this was the June 2010 label, but I actually looked last
11:54:56	5	night and the most recent
	6	MR. BAYMAN: Your Honor, you restricted the evidence.
	7	THE COURT: There's no question pending, Doctor. I'm
	8	afraid you're going to have to wait for a question.
	9	THE WITNESS: I apologize, Your Honor.
11:55:09	10	MR. WISNER: Well, I guess I have to ask the question
	11	and see if
	12	THE COURT: No, you won't.
	13	MR. WISNER: Okay.
	14	THE COURT: You ask your question.
11:55:18	15	MR. WISNER: Okay. I'll move on.
	16	THE COURT: You ask the questions, he gives the
	17	answers.
	18	MR. WISNER: Yes, Your Honor.
	19	THE COURT: That's the way it works.
11:55:23	20	MR. WISNER: I just don't want to ask a question that
	21	gets me in trouble.
	22	THE COURT: Well, and that's why we don't allow the
	23	witness to volunteer.
	24	BY MR. WISNER:
11:55:31	25	Q. Okay. Dont' answer this question until he's objected.

		Ross - direct by Wisner 1212
	1	A. I understand.
	2	Q. Does the current label for Paxil still have this emotional
	3	lability language in it?
	4	A. The most recent label was approved in the labeling
11:55:45	5	supplement was approved in January of 2017. And so that is
	6	like all other versions of the label, available on the web. It
	7	still contains the same language.
	8	Q. 2017?
	9	A. That would be about 2 months ago.
11:55:59	10	Q. So we're 25 years later, from 1992, and to this very day
	11	the label has never told people that emotional lability is
	12	referring to suicide attempts, is that right?
	13	A. That's correct.
	14	Q. All right. Let's continue. Let's go to page 37, Doctor.
11:56:28	15	And we went sorry, let's go back to 36. This is a
	16	nervous system and then there's all these other sections of the
	17	body, right?
	18	A. Organ systems, yes.
	19	Q. Okay. And then we get to the next page, page 37, and after
11:56:44	20	the various organ systems there's one that says "Postmarketing
	21	Reports," do you see that?
	22	A. Yes.
	23	Q. And I don't want to spend much time on this, Doctor,
	24	because I don't want to take up everyone's entire day, but what
11:56:56	25	is a postmarketing report, generally?

Ross - direct by Wisner

1213

	1	A. So once the product is approved, a product drug is
	2	approved, it gets out into general use and can be and is used
	3	not only for the indications that were studied, but also other
	4	indications that may or may not have been studied. It's used
11:57:25	5	in groups of patients who it's never been tested on, and so on.
	6	So the FDA has a system in place where adverse events
	7	that happened in practice, in the real world, are collected.
	8	It's all voluntary. So it's estimated that only, at best, 10
	9	percent of side effects in the real world ever get reported, at
11:57:51	10	most. They can be sent to the manufacturer who turns them into
	11	the FDA. They can be sent directly to the FDA. And there's a
	12	standard form for doing this.
	13	Q. And actually this is a question about the FDA that I want
	14	to clarify. Does the FDA only collect data from
11:58:09	15	placebo-controlled trials?
	16	A. No; of course not.
	17	Q. What other types of data do they collect about suicide
	18	risks or adverse events?
	19	A. Anything. First off, randomized controlled trials are very
11:58:25	20	useful, but they are not the only source of evidence, by any
	21	means.
	22	Secondly, randomized controlled trials only study a
	23	narrow carefully defined population. So it's important to know
	24	how a product is going to be used and what happens in the real
11:58:43	25	world. So these adverse event reports say what happens when

		Ross - direct by Wisner 1214
	1	you get out of the lab and go into the real world.
	2	Q. Scientifically, do you think it's appropriate, both from a
	3	scientific perspective as well as ethical perspective, to
	4	exclude looking at data of an adverse event just because it
11:59:08	5	didn't happen in a placebo-controlled trial?
	6	MR. BAYMAN: Objection, Your Honor, to "ethical."
	7	MR. WISNER: I think this is a part of science, Your
	8	Honor.
	9	THE COURT: Well, I'm going to sustain. We're not
11:59:20	10	going to get into the ethics.
	11	MR. WISNER: Fair enough.
	12	THE COURT: I know there's an ethical problem, but, I
	13	mean, in every activity, but we haven't opened that door yet.
	14	So stay with the relevant part of your question.
11:59:34	15	BY MR. WISNER:
	16	Q. Let me ask the question again, Doctor.
	17	Is there is it scientifically legitimate to just
	18	look at suicides or suicide attempts that occur in
	19	placebo-controlled clinical trials?
11:59:57	20	A. No.
	21	Q. All right. So we have postmarketing reports, and then we
	22	get into this next big section here, Doctor, "drug abuse and
	23	dependence," do you see that?
	24	A. Yes.
12:00:07	25	Q. And then we get to overdosage, do you see that?

		Ross - direct by Wisner 1215
	1	A. Yes.
	2	Q. What is the purpose of the overdosage section?
	3	A. Overdosage provides information for patients and physicians
	4	about whether there's any information on what happens if
12:00:28	5	somebody takes too much of a drug, and also what kind of things
	6	that results in terms of symptoms, and then what to do about
	7	it.
	8	Q. Now, it says here:
	9	" since the introduction of Paxil in the
12:00:43	10	United States, 342 spontaneous cases of
	11	deliberate or accidental overdosage during
	12	Paroxetine treatment have been reported
	13	worldwide circa 1991."
	14	Circa 1991, what does that suggest about what this
12:01:02	15	data is referring to?
	16	A. No information
	17	MR. BAYMAN: Objection, Your Honor. I just want to
	18	make another I think I have a standing objection to the
	19	entire exhibit, but I just want to make it clear we're now
12:01:12	20	going into another area
	21	THE COURT: I don't think dosage is an issue in this
	22	case and I'll sustain your objection. I don't think we should
	23	go into dosage.
	24	MR. WISNER: Your Honor
12:01:20	25	MR. BAYMAN: I ask the jury to disregard his comments

		Ross - direct by Wisner 1216
	1	about that.
	2	MR. WISNER: Your Honor, it says "deliberate or
	3	accidental overdosage," deliberate overdosage is a suicide
	4	attempt.
12:01:33	5	THE COURT: There's never been an issues, as I
	6	understand the case, with all the issues and problems we have,
	7	when the idea of dosage has been contested.
	8	MR. WISNER: Absolutely, Your Honor. We're talking
	9	about fair enough. I'll move on.
12:01:47	10	BY MR. WISNER:
	11	Q. Okay. Great. All right, in the next section here, Doctor,
	12	is "dosage and administration," do you see that?
	13	A. Yes.
	14	Q. And this is one of the last sections of the label. What
12:02:08	15	does that refer to?
	16	A. So this is how much of a dose to start with, whether you
	17	should take it with food, how many times a day. It may depend
	18	on what exact condition you're treating, who you're treating,
	19	how frequently you should make changes to the dose.
12:02:31	20	Q. Now, it says "administration," do you see that?
	21	A. Yes.
	22	Q. Is that about how you give a drug to somebody?
	23	A. Yes.
	24	Q. And do you believe that there are Paxil-specific
12:02:40	25	information that a prescriber would need about how to properly

		Ross - direct by Wisner 1217
	1	administer Paxil, particularly in the early part of the
	2	treatment?
	3	A. Well, let me yes, in in the sense yes.
	4	Q. What is that?
12:02:57	5	A. So again
	6	MR. BAYMAN: Your Honor, again getting into dosage.
	7	THE COURT: I'm going to sustain the objection. We've
	8	got a lot of issues in the case, we don't need to get into
	9	dosage.
12:03:11	10	MR. WISNER: Yes, Your Honor.
	11	BY MR. WISNER:
	12	Q. All right. Okay. So let's go to the last part of the
	13	label, Doctor.
	14	This is a section that's included, it's called the
12:03:23	15	"medication guide," do you see that, Doctor?
	16	It's on page 42.
	17	A. Yes.
	18	Q. What is a medication guide?
	19	MR. BAYMAN: Your Honor, objection. Again, Dr. Ross
12:03:33	20	had no opinions about this, and I just would like a continuing
	21	objection to this line of inquiry.
	22	MR. WISNER: I think he's made that continuing
	23	objection for the last hour. I don't know why he keeps making
	24	it.
12:03:44	25	MR. BAYMAN: Well, it's a different document, Your

		Ross - direct by Wisner 1218
	1	Honor, which is why.
	2	THE COURT: Is the medication guide been an issue in
	3	the case?
	4	MR. BAYMAN: No, sir.
12:03:51	5	MR. WISNER: It they stipulate to not discussing or
	6	mentioning the medication guide in any way, we will not discuss
	7	it now.
	8	THE COURT: They don't have to stipulate. You'll
	9	object and I'll sustain your objection.
12:04:00	10	MR. WISNER: Sounds good, Your Honor.
	11	THE COURT: All right.
	12	BY MR. WISNER:
	13	Q. All right. So, Doctor, we just went through the label and
	14	pointed out, I think we got up to 11 or 12 times places that
12:04:14	15	GSK could have added an adult suicide warning over the age
	16	of 24, is that right?
	17	A. Correct.
	18	Q. Okay. And on the first page here we highlight, we
	19	underline in red and we did it in a couple of other sections as
12:04:26	20	well, portions that you thought were really a problem, is that
	21	right?
	22	A. Correct.
	23	Q. Now I want to clarify something. The statement here as it
	24	relates to all antidepressants, is that itself untrue?
12:04:40	25	A. No.

		Ross - direct by Wisner 1219
	1	Q. The statement, if you'll apply it to Paxil, is it untrue?
	2	A. Yes.
	3	Q. What, if anything, does that how does that relate to
	4	your opinion?
12:04:52	5	A. If you don't give that information, it is misleading.
	6	Q. All right. In a minute I'm going to pass you along to
	7	opposing counsel and there's going to be a discussion of this
	8	section, before that happens I want to just quickly run through
	9	it very quickly with you, Doctor, okay.
12:05:20	10	This first section right here where it says warnings,
	11	clinical worsening and suicide risk, do you see that?
	12	A. Yes.
	13	Q. And it has a discussion in here, do you see that?
	14	A. Yes.
12:05:32	15	Q. All right. And it discusses:
	16	" patients with major depressive disorder,
	17	both adult and pediatric, may experience
	18	worsening of their depression and/or emergence
	19	of suicidal ideation and behavior, suicidality,
12:05:44	20	or unusual changes in behavior whether or not
	21	they are taking antidepressant medications, and
	22	this risk may persist until significant
	23	remission occurs."
	24	Now, this is the language that we talked about
12:05:55	25	yesterday for quite some length, isn't it?
		4

		Ross - direct by Wisner 1220
	1	A. Yes.
	2	Q. Do you believe this language right here is stating to
	3	physicians that Paxil can induce adult suicidal behavior?
	4	A. It's not specific. It doesn't say anything specific about
12:06:08	5	Paxil.
	6	Q. Does it say anything specific about drugs actually doing
	7	anything?
	8	A. No.
	9	Q. In fact, Doctor, the sentence we just read it says:
12:06:20	10	" whether or not they are taking
	11	antidepressant medications."
	12	Do you see that?
	13	A. Yes.
	14	Q. Does that in any way suggest what does that suggest to
12:06:29	15	you?
	16	MR. BAYMAN: Your Honor, I think we covered this 3 or
	17	4 times.
	18	THE COURT: Yeah, I think you covered this, sir.
	19	BY MR. WISER:
12:06:36	20	Q. All right. Let's talk about this page here, this page we
	21	did not cover.
	22	Is there anything in this part of the class warning
	23	that is misleading? We're on page 12, Doctor.
	24	A. Yes.
12:06:48	25	Q. That is misleading or inappropriate without a

		Ross - direct by Wisner 1221
	1	Paxil-specific warning?
	2	A. Yes.
	3	Q. Can you please point it out to us.
	4	A. So this table is for all antidepressants as a group. And
12:07:03	5	it says people who get an antidepressant people under 24 who
	6	get an antidepressant, you may see more suicide.
	7	Q. You are referring to this portion right here, Doctor
	8	(indicating)?
	9	A. Correct.
12:07:17	10	Q. Okay.
	11	A. For all antidepressants as a group more than placebo, but
	12	if you once you get over 25, it's less.
	13	Q. So it says here "one fewer case," does that mean for
	14	patients 25 to 64 the use of antidepressants decreases suicidal
12:07:38	15	behavior?
	16	A. That is what this table says, but it's for antidepressants
	17	as a group.
	18	Q. So, Doctor, is it all right if I circled that one fewer
	19	case right there in red (indicating)?
12:07:51	20	A. Yes.
	21	Q. Does this sentence or this statement hold true when it
	22	comes to Paxil?
	23	A. No.
	24	Q. What do we know about Paxil?
12:07:59	25	A. It increases the risk.

		Ross - direct by Wisner 1222
	1	Q. Specifically, what do we know about Paxil for this age
	2	group?
	3	A. We know that that increases the risk.
	4	Q. All right. Is there anything else in this that you think
12:08:13	5	needs to be pointed out to the jury?
	6	A. I would just say just one other thing, and I just want to
	7	make this very, very clear, as I said yesterday, the label is
	8	in terms of how the FDA considers this, there's these
	9	concerns regarding the label extend to things are, from a
12:08:39	10	regulatory point of view, part of the label, such as
	11	advertising, print ads. And if I'm trying to clarify this,
	12	and if I'm I don't want to go beyond the line here, but the
	13	medication guide is part of the labeling
	14	MR. BAYMAN: Your Honor, we just objected to the
12:09:02	15	medication guide and you sustained the objection. That was the
	16	last document which he wanted me to stipulate to and you
	17	sustained my objection.
	18	THE COURT: Yes. It's not clear what the point is
	19	here, sir. Ask another question.
12:09:13	20	MR. WISNER: Sure.
	21	BY MR. WISNER:
	22	Q. Doctor, my question was, is there any specific sentences in
	23	this section of the label that I should highlight to the jury?
	24	A. Is there any
12:09:27	25	THE COURT: I think we've been over this, sir.

		Ross - direct by Wisner 1223
	1	MR. WISNER: No, this actually we have not covered.
	2	BY MR. WISER:
	3	Q. Let me just draw your attention.
	4	Doctor, the sentence right here, "there were
12:09:37	5	suicides," do you see that?
12.09.37	6	A. Yes.
	7	Q. Do you have a problem with that sentence?
	8	A. Yes, I do.
	9	Q. What's your problem with that sentence?
12:09:41	10	A. There were suicides in the adult trials but the number was
	11	sufficient to reach any conclusion about drug effect on
	12	suicide, that is not true for Paxil.
	13	Q. What do we know about Paxil?
	14	A. Paxil increases the risk of suicide in adults at all ages,
12:09:57	15	including adults older than 24.
	16	Q. And can I bracket that or is that not
	17	A. Please.
	18	Q. All right. Okay, Doctor, and the rest of this we covered
	19	yesterday, so I don't want to get into it in any detail. Do
12:10:11	20	you believe that this constitutes a warning about
	21	antidepressants or does it constitute disease management?
	22	A. Disease management.
	23	Q. Okay. All right.
	24	MR. WISNER: Your Honor, at this time I'm going to
12:10:37	25	mark this as Plaintiff's Exhibit 70. And this is the markup

		Ross - direct by Wisner 1224
	1	version I was discussing with Dr. Ross.
	2	And one second.
	3	(Whereupon, there was a conference had between
	4	counsel off the record.)
12:10:55	5	MR. WISNER: At this time, Your Honor, we move
	6	Plaintiff's Exhibit 70 into evidence.
	7	MR. BAYMAN: I object to that, Your Honor. That's the
	8	marked up version which is demonstrative.
	9	THE COURT: You may use it at some other point in the
12:11:06	10	trial, sir, but I'm going to receive it in evidence, as such.
	11	We already have the unmarked-up-exhibit in evidence,
	12	we have the record, we have the doctor's testimony. So we will
	13	not receive it in evidence. You may have some use of it for
	14	demonstrative purposes.
12:11:24	15	MR. WISNER: Sure. Sounds good.
	16	(Brief pause).
	17	THE COURT: Do you want to start your
	18	cross-examination, sir?
	19	MR. WISNER: I have a few more points and then I'm
12:11:35	20	done.
	21	THE COURT: I thought you had tendered the witness.
	22	MR. WISNER: No, not yet at this time, Your Honor.
	23	THE COURT: We're trying to help you, sir.
	24	MR. WISNER: I know. I'm just moving over to my other
12:11:43	25	device because I'm no longer using the camera.

		Ross - direct by Wisner 1225
	1	THE COURT: All right. Proceed.
	2	BY MR. WISER:
	3	Q. Okay, Doctor, we just went through that label. Have you
	4	seen any statements publicly made by GSK employees that they
12:11:59	5	have not warned about drug-induced suicidality in the label?
	6	A. Yes.
	7	MR. BAYMAN: Objection, Your Honor. That's not
	8	disclosed. It goes into motive and intent and it's also
	9	hearsay.
12:12:12	10	MR. WISNER: It is in his report and I can show you
	11	the page site, if you'd like.
	12	THE COURT: Just a minute.
	13	(Brief pause).
	14	THE COURT: All right. You may proceed.
12:12:24	15	BY MR. WISER:
	16	Q. Are you aware of any statement made by GSK, Doctor?
	17	A. Yes.
	18	Q. And where was that statement made?
	19	A. That was made in a publication by GSK employees that was
12:12:43	20	I believe it was the Journal of Clinical Psychopharmacology.
	21	It was submitted to that journal in 2008, I believe published
	22	in either 2010 or 2011. The first author on that, I believe,
	23	was Mr. Krause.
	24	Q. All right, Doctor, could you please turn in your binder to
12:13:09	25	Plaintiff's Exhibit 285.

		Ross - direct by Wisner 1226
	1	(Brief pause)
	2	BY MR. WISNER:
	3	Q. Are you there?
	4	A. Iam.
12:13:31	5	Q. Is this that article you were referring to?
	6	A. It is. I apologize, the first author was Mr. Carpenter.
	7	Q. Okay. Is this document that you cited in your report?
	8	A. Yes.
	9	Q. Is this a document that you relied upon in forming your
12:13:48	10	opinions?
	11	A. Yes.
	12	Q. Would discussing the contents of this document aid you in
	13	your testimony today?
	14	A. Yes.
12:13:53	15	MR. WISNER: Permission to publish, Your Honor.
	16	THE COURT: All right.
	17	(Exhibit published to the jury.)
	18	BY MR. WISER:
	19	Q. So we're looking at the journal article here, Doctor. I'm
12:14:03	20	just going to call out the title and the authorship here.
	21	What is the title on this document, doctor?
	22	A. (Reading:)
	23	' meta analysis of efficacy and treatment
	24	emergent, suicidality in adults by psychiatric
12:14:15	25	indication and age subgroup following initiation

		Ross - direct by Wisner 1227
	1	of Paroxetine therapy: A complete set of
	2	randomized placebo-controlled date trials."
	3	Q. What does that mean in layman's terms?
	4	A. They combined all the trials and they looked to see if
12:14:32	5	people who received Paxil were more likely to kill themselves
	6	or try to kill themselves compared to placebo and they looked
	7	at it by age as well.
	8	Q. Okay. Great. And you mentioned the authors here. I want
	9	to point out one. Do you see this person, John Kraus?
12:14:53	10	A. Yes.
	11	Q. Who is he?
	12	A. Dr. Kraus is a GSK employee.
	13	Q. And was he heavily involved in the 2006 analysis that
	14	yielded that 6.7 risk ratio we discussed yesterday?
12:15:14	15	A. Yes.
	16	Q. Okay. Let's look at this first paragraph here and just
	17	to be clear, Doctor, you said this was published when?
	18	A. I'm sorry, it was accepted in 2010 and then published in
	19	2011.
12:15:33	20	Q. Okay. So this was was this after or before the class
	21	warnings that were instituted by the FDA?
	22	A. After.
	23	Q. Okay. So this is hard to read, but let's see if I can do
	24	it. It says:
12:15:50	25	" while these agents are efficacious and

		Ross - direct by Wisner 1228
	1	generally well tolerated, standard precautionary
	2	statements regarding suicidality have existed in
	3	SSRI and other antidepressant prescribing
	4	medication for more than a decade."
12:16:07	5	Do you see that, Doctor?
	6	A. Yes.
	7	Q. Is it your understanding that there had been standard
	8	precautionary kind of suicidal warnings in SSRIs for over a
	9	decade?
12:16:20	10	A. If they're talking about the only with regard to the
	11	disease itself, not with regard to the potential for a drug
	12	to one of these drugs to induce suicide.
	13	Q. Well, let's go to the next sentence:
	14	" these precautions, however, did not
12:16:46	15	explicitly alert prescribers to the potential
	16	that the medication itself could induce
	17	suicidality."
	18	Do you see that, Doctor?
	19	A. Yes.
12:16:54	20	Q. How does that in any way relate to the opinions you gave
	21	this jury about whether the Paxil label addresses whether Paxil
	22	itself induces adult suicidal behavior?
	23	MR. BAYMAN: Objection, Your Honor. This is talking
	24	about the early label. Not the 2010 label, it's very clear.
12:17:11	25	THE COURT: I beg your pardon. I didn't quite hear

		Ross - direct by Wisner 1229
	1	what you said.
	2	MR. BAYMAN: I'm sorry. Objection, Your Honor, he is
	3	mischaracterizing this. This talks about the early label, not
	4	the label that he was questioned about. It is misleading.
12:17:25	5	THE COURT: Okay. Well, you can cover that on cross
	6	examination.
	7	You may answer.
	8	THE WITNESS: I'm sorry, could you read the question
	9	back to me.
12:17:40	10	(Question read.)
	11	BY THE WITNESS:
	12	A. Well, I think it's an acknowledgement, admission, whatever,
	13	that the statements in the label for Paxil have never, not just
	14	in '92 but going forward as I said yesterday, never explicitly
12:18:04	15	alerted or even hinted at the potential that Paxil could induce
	16	suicidality.
	17	BY MR. WISNER:
	18	Q. All right. We talked a bit about whether or not there was
	19	any analysis that looked at whether Paxil increased suicidality
12:18:19	20	or suicidal behavior in adults specifically over 24, remember?
	21	A. Correct.
	22	Q. Let's take a look at this article.
	23	All right, Doctor, I'm on page E7 of this article.
	24	And I called up a table here, table 6, what is it titled,
12:18:55	25	Doctor? I have it blown up on the screen if you want to look.


		Ross - direct by Wisner 1230
	1	
	2	Your copy might be clearer because it's a little blurry here.
	2	(Brief pause).
	4	BY THE WITNESS:
40.40.00	- 5	A. Yes.
12:19:06	6	BY MR. WISNER:
	7	Q. So what's the title of that table?
	8	A. (Reading:)
	9	" "definitive suicidal behavior or ideation
12:19:13	10	by indication, treatment, and age as a risk
12.19.13	11	factor."
	12	Q. All right. And if you look here, we have ages 25 through
	13	64, do you see that, Doctor?
	14	A. Yes.
12:19:30	15	Q. Okay. So now we're looking specifically at that age
12.19.30	16	bracket that we were talking about a minute ago.
	17	A. Yes.
	18	Q. Okay. And then we have MDD, do you see that?
	19	A. Yes.
12:19:41	20	Q. All right. And then it lists all the data for it. And if
12.10.41	21	we look over here sorry. I had the wrong part.
	22	If we look at over here, under the section "definitive
	23	suicidal behavior," do you see the number presented for MDD?
	24	A. Yes.
12:20:07	25	MR. BAYMAN: Objection. I object to this line, Your
12.20.01	_~	

		Ross - direct by Wisner 1231
	1	Honor, also. This is not in his expert report, or in any of
	2	his disclosed opinions, nor in his deposition testimony. So I
	3	object to this entire line.
	4	MR. WISNER: For the record, it is in his report. He
12:20:21	5	cites this article. And they never questioned him at his
12.20.21	6	deposition.
	7	THE COURT: Proceed.
	8	BY MR. WISER:
	9	Q. All right, Doctor, do you see this line here that it refers
12:20:29	10	to MDD and definitive suicidal behavior alone?
12.20.29	11	A. Yes.
	12	Q. All right. I'm just going to blow that up even closer so
	13	that we can all see it.
	14	So on the left side we have the incident rates for
40,00,40	15	Paxil, is that right?
12:20:42	16	A. Yes.
	17	
		Q. And then in the middle we have placebo, is that right?
	18	A. Yes.
	19	Q. 8 on Paxil, zero on placebo, is that right?
12:20:54	20	A. That's correct.
	21	Q. And then a risk ratio represented in the far right, do you
	22	see that?
	23	A. Yes.
	24	Q. It says "infinity," is that right?
12:21:03	25	A. That's correct.

		Ross - direct by Wisner 1232
	1	Q. What does that mean from a statistical perspective?
	2	MR. BAYMAN: Same objection, Your Honor.
	3	THE COURT: Overruled.
	4	BY THE WITNESS:
12:21:11	5	A. So just want to be clear about what we're looking at the
	6	risk up here
	7	BY MR. WISNER:
	8	Q. Doctor, please answer my question.
	9	A. Okay. Okay.
12:21:19	10	Q. What does "infinity" mean here?
	11	A. "Infinity" means that it's an extraordinarily high risk.
	12	And if you look at the confidence interval, that lower number
	13	of 1.3 means that we can be sure about that, that this is not
	14	just a chance finding.
12:21:36	15	Q. So to be clear, Doctor, GSK's own employee, Dr. Kraus,
	16	published an article that acknowledged that the definitive
	17	suicidal behavior for people over the age 24 but under 65,
	18	there was a nonrandom increased risk in suicidal behavior, is
	19	that right?
12:21:58	20	MR. BAYMAN: Objection; leading, Your Honor.
	21	THE COURT: Overruled.
	22	BY THE WITNESS:
	23	A. Yes.
	24	BY MR. WISER:
12:22:04	25	Q. Since this article was published or proposed for

		Ross - direct by Wisner 1233
	1	publication in 2008, did GSK ever add a warning about
	2	definitive suicidal behavior in adults over the age of 24?
	3	A. So just to make sure I understand. By "definitive suicidal
	4	behavior," you mean not just the way it's defined, it's just
12:22:27	5	behavior but combined by suicide attempts and completed
	6	suicides?
	7	Q. That's right. I'm talking about in the chart, it says
	8	"definitive suicidal behavior," did GSK
	9	A. No. No. Absolutely not.
12:22:38	10	Q. All right. Let me ask just ask the question so we get the
	11	record clear.
	12	A. Sure.
	13	Q. Since this article was prepared in 2008, did GSK ever put
	14	in the
12:22:48	15	MR. BAYMAN: Your Honor, objection. This is 2011, the
	16	article clearly states that. It's not 2008, it's 2011 after
	17	the events leading to
	18	MR. WISNER: Your Honor, it was submitted it 2008.
	19	He's testified to that several times.
12:23:00	20	MR. BAYMAN: It was published in 2011, Your Honor.
	21	It's clear on the document.
	22	THE COURT: Submitted when?
	23	MR. BAYMAN: It's published in 2011, Your Honor. On
	24	the first page of the document, which is, I think, beyond the
12:23:14	25	event. It was accepted May 26, 2010 and it was published in

		Ross - direct by Wisner 1234
	1	2011. It says clearly on the article
	2	MR. WISNER: Respectfully, Your Honor, it says
	3	submitted December 8, 2008. So this was prepared over 2 years
	4	before his death.
12:23:32	5	THE COURT: Yes.
	6	MR. BAYMAN: And published after his death, Your
	7	Honor.
	8	THE COURT: I understand.
	9	BY MR. WISER:
12:23:38	10	Q. All right, Doctor, let me ask you my question. Let's go
	11	back to this table.
	12	Doctor, after this was submitted for publication in
	13	2008, did GSK ever attempt to put a warning for adults over the
	14	age of 24 for definitive suicidal behavior in the Paxil
12:24:04	15	labeling?
	16	A. No.
	17	Q. Has GSK in the entire 30 years that this drug has been on
	18	the market ever put in the label that this drug can cause
	19	adults to kill themselves?
12:24:16	20	A. With the clarification that it's actually a quarter century
	21	rather than 30 years, no.
	22	MR. WISNER: Thank you, Your Honor.
	23	One minute, Your Honor. Let me check with counsel.
	24	(Brief pause).
12:24:29	25	MR. WISNER: We pass the witness.



	Ross - direct by Wisner 1	236
1		
2		
3	* * * * * * * *	
4		
5		
6	I CERTIFY THAT THE FOREGOING IS A CORRECT TRANSCRIPT FROM T	HE
7	RECORD OF PROCEEDINGS IN THE ABOVE-ENTITLED MATTER	
8		
9		
10		
11	S/Blanca I. Lara March 22, 2017	
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		